SEARCH
検索詳細
中村 順一 (ナカムラ ジユンイチ)
| 北海道大学病院 内科 | 助教 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
- 50933743
研究活動情報
■ 論文- Sex Differences in Clinical Presentation and Outcomes in Chronic Thromboembolic Pulmonary Hypertension
Keiji Kimuro; Kohei Masaki; Masayuki Hirose; Takumi Inami; Yu Taniguchi; Shiro Adachi; Kazuya Hosokawa; Jun Yamashita; Taijyu Satoh; Junichi Nakamura; Shun Minatsuki; Nobutaka Ikeda; Naohiro Komura; Yoshihiro Dohi; Nobuhiro Tanabe; Ayako Shigeta; Kayoko Kubota; Yoshito Ogihara; Koshin Horimoto; Hiroto Shimokawahara; Yuki Ueno; Yuichi Tamura; Atsushi Anzai; Kimi Sato; Hidekazu Ikemiyagi; Yoichi Sugiyama; Yoshihiro Fukumoto; Hakuo Konishi; Kazuhiro Kimura; Toshiro Shinke; Kazuto Nakamura; Yuichi Baba; Koichiro Sugimura; Koichi Sugimoto; Eiichiro Yamamoto; Noriaki Takama; Noriko Kikuchi; Yoshiharu Sada; Soichiro Usui; Kohtaro Abe; Keiji Kimuro; Kohei Masaki; Masayuki Hirose; Takumi Inami; Yu Taniguchi; Shiro Adachi; Kazuya Hosokawa; Jun Yamashita; Taijyu Satoh; Junichi Nakamura; Shun Minatsuki; Nobutaka Ikeda; Naohiro Komura; Yoshihiro Dohi; Nobuhiro Tanabe; Ayako Shigeta; Kayoko Kubota; Yoshito Ogihara; Koshin Horimoto; Hiroto Shimokawahara; Yuki Ueno; Yuichi Tamura; Atsushi Anzai; Kimi Sato; Hidekazu Ikemiyagi; Yoichi Sugiyama; Yoshihiro Fukumoto; Hakuo Konishi; Kazuhiro Kimura; Toshiro Shinke; Kazuto Nakamura; Yuichi Baba; Koichiro Sugimura; Koichi Sugimoto; Eiichiro Yamamoto; Noriaki Takama; Noriko Kikuchi; Yoshiharu Sada; Soichiro Usui; Kohtaro Abe; Kohtaro Abe
JACC: Asia, 2026年11月
研究論文(学術雑誌) - Prognostic impact of coexisting lung disease in patients with pulmonary arterial hypertension
Taku Komori; Takahiro Sato; Shuhei Yoshikawa; Tomohiko Nakamura; Junichi Nakamura; Hirokazu Kimura; Kenichiro Suzuki; Ichizo Tsujino; Satoshi Konno
Respiratory Medicine, 2026年11月
研究論文(学術雑誌) - Efficacy of short-term, low-dose pulmonary vasodilators for chronic thromboembolic pulmonary hypertension: a retrospective pilot study.
Hideki Shima; Takahiro Sato; Ichizo Tsujino; Shuhei Yoshikawa; Taku Komori; Junichi Nakamura; Isao Yokota; Satoshi Konno
Respiratory investigation, 64, 4, 101473, 101473, 2026年07月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is treated with pulmonary endarterectomy, pulmonary vasodilators (PVs), and balloon pulmonary angioplasty (BPA). PV therapy may be initiated before BPA; however, dose adjustment can delay BPA. Therefore, short-term, low-dose administration is sometimes used to enable earlier BPA; however, its efficacy and safety remain unclear. METHODS: Twenty patients with World Health Organization functional class III/IV CTEPH, who received low-dose PVs (riociguat or selexipag) and underwent right heart catheterization and first BPA within 60 days, were retrospectively analyzed. Hemodynamic parameters and brain natriuretic peptide (BNP) levels were compared before and after PV therapy. First-session BPA complications were evaluated. RESULTS: After a median of 18 days of therapy, mean pulmonary arterial pressure (mPAP) decreased from 42 to 40 mmHg (mean difference, -2.1 mmHg; 95% confidence limits [CL], -4.2 to -0.02; p = 0.0482), pulmonary vascular resistance (PVR) decreased from 829 to 632 dyne s·cm-5 (mean difference, -197 dyne s·cm-5; 95% CL, -227 to -117; p < 0.0001), and BNP decreased from 284 to 146 pg/mL (mean difference, -139 pg/ml; 95% CL, -203 to -75; p = 0.0002). Cardiac output and cardiac index increased significantly. Higher baseline mPAP and PVR values were associated with greater reductions in the corresponding parameters. BPA-related complications occurred in four patients (20%), all of which involved hemoptysis from peripheral lesions. CONCLUSION: Short-term, low-dose PV therapy before BPA was associated with improvements in hemodynamic parameters and BNP levels. Baseline mPAP, PVR, and cardiac index may predict treatment response. Prospective studies are needed to refine pre-BPA strategies. - Real-world treatment practices of selexipag and parenteral prostacyclin (PGI2) analogs for pulmonary arterial hypertension in Japan: Retrospective study of the Japan PH Registry.
Yuichi Tamura; Hiraku Kumamaru; Kohji Murakami; Koichi Matsuoka; Seiya Ohtani; Takumi Inami; Junichi Nakamura; Kohtaro Abe; Yu Taniguchi; Ayako Shigeta; Hiromi Matsubara
Journal of cardiology, 88, 1, 29, 37, 2026年07月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: In treatment of pulmonary arterial hypertension (PAH), the prostacyclin (PGI2) pathway is targeted by oral selexipag and parenteral PGI2 analogs. Although guidelines recommend therapeutic strategies based on disease severity and etiology, there are limited data on real-world use of selexipag and parenteral PGI2 analogs in Japan. This study aimed to characterize the use of these drugs in treatment of PAH in Japan, with a focus on differences related to patient characteristics and PAH etiology. METHODS: Patients with PAH registered in the Japan PH Registry (JAPHR) from November 2016 to March 2023 were evaluated. Patients who met the inclusion criteria were further stratified by PAH etiologies, drug used, severity of disease, treatment strategies, time from diagnosis to drug initiation, and pulmonary hemodynamics. RESULTS: A total of 235 patients were treated with selexipag and 121 patients with parenteral PGI2. Selexipag and parenteral PGI2 analogs were most frequently used for idiopathic PAH (IPAH) or heritable PAH (HPAH), at 56.2 % (132/235) and 82.6 % (100/121), respectively. Selexipag was also used more frequently than parenteral PGI2 analogs for PAH associated with connective tissue disease and congenital heart disease. Most patients received triple therapy, with 76.2 % (179/235) and 59.5 % (72/121) receiving selexipag and parenteral PGI2 analogs, respectively. Regarding New York Heart Association functional class (NYHA-FC), selexipag was primarily administered to Class II-III patients and parenteral PGI2 analogs to Class III patients. Both mean pulmonary artery pressure and pulmonary vascular resistance values were lower in the selexipag group than in the parenteral PGI2 group. CONCLUSION: Parenteral PGI2 analogs tend to be used mainly in patients with severe IPAH/HPAH, while selexipag is used in patients with a broader range of etiologies around NYHA-FC II-III. Choice of selexipag and parenteral PGI2 analogs for treatment of PAH is influenced by disease severity and etiology. - Prognostic impact of 18F-fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance-proven cardiac involvement in pulmonary sarcoidosis: a single centre long-term cohort study.
Shuhei Yoshikawa; Takahiro Sato; Taku Komori; Junichi Nakamura; Osamu Manabe; Noriko Oyama-Manabe; Satonori Tsuneta; Hirokazu Kimura; Sakae Takenaka; Toshiyuki Nagai; Toshihisa Anzai; Isao Yokota; Ichizo Tsujino; Satoshi Konno
BMC pulmonary medicine, 2026年06月29日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Sarcoidosis is a systemic granulomatous disease, often affecting the lungs, with a generally favourable prognosis. However, some patients experience progressive disease, and cardiac involvement may worsen outcomes. Data on the clinical course and causes of death in pulmonary sarcoidosis (PS), particularly with coexisting cardiac sarcoidosis (CS), remain limited. METHODS: We retrospectively analysed patients with histologically confirmed PS. Baseline evaluations included chest X-ray and computed tomography, pulmonary function tests, and echocardiography. CS was diagnosed based on the findings of 18F-fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance imaging in patients who met the predefined clinical screening criteria. RESULTS: A total of 513 patients met the study criteria. The 3-, 5-, and 10-year survival rates were 98.2%, 97.0%, and 94.6%, respectively (median follow-up: 6.7 years). CS was diagnosed in 48 patients (9.4%), and survival was poorer in those with CS (p = 0.004 by log rank test). Multivariate analysis showed that CS was associated with increased all-cause mortality after adjustment for age or sex (age-adjusted hazard ratio 3.55, 95% CI 1.18-10.6; sex-adjusted hazard ratio 3.79, 95% CI 1.28-11.2). During follow-up, 21 patients (4.6%) died. Malignancy was the leading cause of death (n = 10, 48%), followed by cardiac death (n = 3, 14%) and respiratory failure (n = 3, 14%). CONCLUSIONS: In this Japanese single-centre cohort of patients with predominantly mild histologically confirmed PS, CS identified through a screening-based diagnostic pathway was associated with increased all-cause mortality. - Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study.
Kazuya Hosokawa; Kohei Masaki; Masayuki Hirose; Takumi Inami; Yu Taniguchi; Shiro Adachi; Keimei Yoshida; Jun Yamashita; Nobuhiro Yaoita; Junichi Nakamura; Shun Minatsuki; Nobutaka Ikeda; Naohiro Komura; Yoshihiro Dohi; Nobuhiro Tanabe; Ayako Shigeta; Kayoko Kubota; Yoshito Ogihara; Koshin Horimoto; Hiroto Shimokawahara; Yuki Ueno; Yuichi Tamura; Atsushi Anzai; Kimi Sato; Hidekazu Ikemiyagi; Yoichi Sugiyama; Hakuoh Konishi; Kazuhiro Kimura; Toshiro Shinke; Kazuto Nakamura; Yuichi Baba; Koichiro Sugimura; Koichi Sugimoto; Eiichiro Yamamoto; Noriaki Takama; Noriko Kikuchi; Yoshiharu Sada; Soichiro Usui; Yoshihiro Fukumoto; Kohtaro Abe
Journal of thrombosis and haemostasis : JTH, 2026年06月18日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Long-term real-world outcomes of edoxaban in chronic thromboembolic pulmonary hypertension (CTEPH) remain incompletely characterized despite emerging evidence, including the KABUKI randomized trial. OBJECTIVES: To evaluate long-term effectiveness and safety of edoxaban in patients with CTEPH using a nationwide registry. METHODS: We analyzed the CTEPH AC Registry, a multicenter prospective observational cohort. Patients with CTEPH receiving edoxaban at registration were included. The primary effectiveness endpoint was morbidity and mortality events, a composite of all-cause death, lung transplantation, rescue pulmonary endarterectomy or balloon pulmonary angioplasty, ≥15% decline in 6-minute walk distance with worsening World Health Organization functional class, or symptomatic venous thromboembolism. The primary safety endpoint was clinically relevant bleeding according to International Society on Thrombosis and Haemostasis criteria. RESULTS: Among 408 patients, median follow-up was 552 days. The cumulative incidence of morbidity and mortality events was 4.7%, 10.0%, and 14.1% at 1, 3, and 5 years, respectively. The cumulative incidence of clinically relevant bleeding was 3.2%, 4.8%, and 5.6%, respectively, and major bleeding occurred in 2.4% at 5 years. Symptomatic venous thromboembolism occurred in 1.5% at 5 years. Outcomes were broadly consistent across reperfusion history, World Health Organization functional class, edoxaban dose, and renal function strata. CONCLUSIONS: In this Japanese nationwide registry, long-term edoxaban therapy was associated with sustained clinical stability in patients with CTEPH. No clear late-emerging safety signal was observed, but extrapolation beyond Japan requires caution, particularly in patients with different body size, renal function, or concomitant medication profiles. - A case of exogenous lipoid pneumonia caused by Vaseline to the tracheostomy in a laryngectomy patient.
Miho Wakazono; Hirokazu Kimura; Takatoshi Suzuki; Nozomu Takei; Kenjiro Kato; Nobuyasu Wakazono; Junichi Nakamura; Sho Nakakubo; Emi Takakuwa; Satoshi Konno
Respiratory medicine case reports, 61, 102416, 102416, 2026年, [国際誌]
英語, 研究論文(学術雑誌), A 65-year-old man, who had undergone laryngectomy two years earlier, was incidentally found to have nodular shadows and ground-glass opacity (GGO) in both lower lobes, identified nine months ago, which gradually progressed. He was diagnosed with lipoid pneumonia based on a transbronchial lung biopsy. The daily application of Vaseline to the tracheostomy site was considered the cause of exogenous lipoid pneumonia. Although GGO improved after the discontinuation of Vaseline use, it persisted 2 years later. This case is notable for its unusually short onset interval of 1.5 years and the longest reported follow-up of Vaseline-induced lipoid pneumonia after laryngectomy. - Pathological features of pulmonary vasculopathy in interstitial lung disease-associated pulmonary hypertension.
Ayako Igarashi-Sugimoto; Ichizo Tsujino; Hideki Shima; Junichi Nakamura; Toshitaka Nakaya; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Kei Takamura; Noriyuki Otsuka; Akihiro Ishizu; Sari Iwasaki; Zenichi Tanei; Mishie Tanino; Koji Taniguchi; Shinya Tanaka; Isao Yokota; Satoshi Konno
Respiratory medicine, 248, 108395, 108395, 2025年11月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The prognosis of interstitial lung disease-associated pulmonary hypertension remains poor, and the characteristics of the vasculopathy and its underlying pathogenesis are unclear. OBJECTIVE: To investigate the pathological characteristics of pulmonary vasculopathy in interstitial lung disease-associated pulmonary hypertension. METHODS: Autopsy specimens were collected from four groups: control (n = 2), pulmonary arterial hypertension (n = 3), interstitial lung disease-associated pulmonary hypertension (n = 6), and interstitial lung disease without pulmonary hypertension (n = 3). The morphology from the arteries to the veins was quantitively compared, along with the expression of pathogenetic factors and target proteins of pulmonary vasodilators. RESULTS: The percent area stenosis of the muscular arteries and veins were 83 % (71 %-92 %) and 54 % (41 %-70 %), respectively, in the interstitial lung disease-associated pulmonary hypertension group, which were not significantly different compared with other groups except controls. In contrast, for microvessels, the percent area stenosis and muscularization rate in moderate fibrotic areas were significantly higher, and capillary multilayering was also more prominent, in the interstitial lung disease-associated pulmonary hypertension group compared with the interstitial lung disease without pulmonary hypertension group. The expression of pathogenetic factors was not different between interstitial lung disease groups with and without pulmonary hypertension; however, prostaglandin I2 receptors were more strongly expressed in the microvessel wall of interstitial lung disease-associated pulmonary hypertension group than in pulmonary arterial hypertension group. CONCLUSIONS: Interstitial lung disease-associated pulmonary hypertension is pathologically characterized by microvessel remodeling and capillary multilayering. Increased expression of prostaglandin I2 receptor in the microvessels suggests different responses to stimulators of the pathway. - Right Ventricular Dysfunction in Lung Disease/Hypoxia-Associated Pulmonary Hypertension.
Hideki Shima; Ichizo Tsujino; Toshitaka Nakaya; Junichi Nakamura; Ayako Igarashi-Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Ryo Hisada; Masaru Kato; Satonori Tsuneta; Isao Yokota; Satoshi Konno
Journal of the American Heart Association, 14, 16, e042186, 2025年08月19日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Limited data exist on right ventricular (RV) function in lung disease/hypoxia-associated pulmonary hypertension (PH). We aimed to clarify the presence, characteristics, and clinical significance of RV dysfunction in patients with lung disease/hypoxia-associated PH. METHODS: We analyzed data from 3 groups of patients: those with lung disease/hypoxia-associated PH, those without PH, and those with pulmonary arterial hypertension (PAH). RV volume was assessed using cardiac magnetic resonance imaging, and RV pressure data were obtained by right heart catheterization and analyzed using dedicated software and a single-beat method. We then evaluated RV contractility by end-systolic elastance (Ees), diastolic function by β and end-diastolic elastance, and RV-pulmonary artery coupling by Ees/arterial elastance. RESULTS: We studied 68 patients with lung disease/hypoxia-associated PH, 40 without PH, and 93 with PAH. In the lung disease/hypoxia-associated PH group, Ees was sustained (0.46 [95% CI, 0.26-0.75] mm Hg/mL), whereas β (0.035 [95% CI, 0.022-0.049]) and end-diastolic elastance (0.19 [95% CI, 0.11-0.38] mm Hg/mL) were higher, and Ees/arterial elastance was lower (0.59 [95% CI, 0.27-0.79]) compared with the no-PH group. There were no differences in these values between the groups with lung disease/hypoxia-associated PH and PAH. Ees/arterial elastance was significantly correlated with the 6-minute walk distance and associated with mortality (hazard ratio, 0.18 [95% CI, 0.04-0.79]) in the group with PAH, but it was not in the group with lung disease/hypoxia-associated PH. Similarly, whereas the group with PAH showed improvement in β and Ees/arterial elastance with pulmonary vasodilator therapy, such improvement was not observed in the group with lung disease/hypoxia-associated PH. CONCLUSIONS: In lung disease/hypoxia-associated PH, RV contractility is preserved, whereas diastolic function and RV-pulmonary artery coupling are impaired. Further investigation is needed to elucidate the distinct clinical relevance of RV dysfunction in lung disease/hypoxia-associated PH. - Two cases of bronchial artery aneurysms in patients with long-standing precapillary pulmonary hypertension.
Taku Komori; Takahiro Sato; Ichizo Tsujino; Daisuke Tamatsuki; Shuhei Yoshikawa; Hideki Shima; Junichi Nakamura; Ryo Morita; Daisuke Abo; Satoshi Konno
Respiratory investigation, 63, 4, 521, 523, 2025年07月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Bronchial artery aneurysm (BAA) is a rare but increasingly recognized condition due to advances in imaging. We report two cases of BAA in patients with long-standing pulmonary hypertension. Case 1 is a 30-year-old man with idiopathic peripheral pulmonary artery stenosis diagnosed at age 23. He developed a slightly dilated bronchial artery, which later enlarged, leading to bronchial artery embolization. Case 2 is a 30-year-old woman with pulmonary arterial hypertension diagnosed at age 3. Multiple BAAs were identified at age 24, and progressive enlargement was observed at age 28. Due to lesion complexity, she remains under careful observation. - Reduced hemoglobin-corrected diffusing capacity in pulmonary arterial hypertension with preserved pulmonary function and morphology.
Ayako Igarashi-Sugimoto; Ichizo Tsujino; Hideki Shima; Junichi Nakamura; Toshitaka Nakaya; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Kaoruko Shimizu; Takashi Yokota; Sari Iwasaki; Satonori Tsuneta; Isao Yokota; Satoshi Konno
Respiratory investigation, 63, 4, 600, 607, 2025年07月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: The diffusing capacity and the transfer coefficient of the lung for carbon monoxide (DLCO and KCO, respectively) are reduced in pulmonary arterial hypertension; however, the effect of pulmonary arterial hypertension alone on these parameters and their clinical impact remain unclear. We aimed to elucidate the exclusive impact of pulmonary arterial hypertension on these two parameters and examine their association with other parameters. METHODS: We retrospectively selected patients with pulmonary arterial hypertension with normal pulmonary function upon pulmonary function testing and with normal lung parenchyma upon chest computed tomography. We calculated the hemoglobin-corrected DLCO (DLCO-Hbc) and KCO (KCO-Hbc) and examined their association with established pulmonary hypertension-related parameters. An exploratory analysis of pulmonary vasculopathy was performed in an autopsy case. RESULTS: We included 50 patients with pulmonary arterial hypertension for analysis. Their median %DLCO-Hbc and %KCO-Hbc were 62 % and 70 %, respectively. The DLCO-Hbc was associated with functional class, 6-min walk distance, alveolar-arterial oxygen tension difference, cardiac output, and pulmonary arterial hypertension-related death. The DLCO-Hbc and KCO-Hbc were also correlated with the lowest minute ventilation/carbon dioxide production ratio (ρ = -0.84 and -0.49, respectively), an index that represents ventilation-perfusion mismatch. The autopsy revealed pulmonary arterial hypertension-specific arteriopathy that was heterogeneously distributed in the lungs. CONCLUSIONS: The DLCO-Hbc and KCO-Hbc were reduced to 60 %-70 % in patients with pulmonary arterial hypertension even when their pulmonary function and morphology were preserved. The decreases were associated with pulmonary hypertension-related clinical parameters and survival and may be caused by heterogeneous vasculopathy and subsequent ventilation-perfusion mismatch. - Klebsiella pneumoniae bacteremic cellulitis following tocilizumab administration for COVID-19.
Takahiro Hase; Ken Muramatsu; Chihiro Shiiya; Chiho Shibusa; Hideyuki Kosumi; Junichi Nakamura; Taku Maeda; Hideyuki Ujiie
The Journal of dermatology, 52, 6, e534-e535, 2025年06月, [査読有り], [国際誌]
英語 - Hypopituitarism Induced by Continuous Infusion of PGI2 Analogues: A Case Series and the Role of ACTH Screening and Hydrocortisone Treatment.
Taijyu Satoh; Yuichi Tamura; Noriaki Takama; Hiromi Matsubara; Nobuhiro Tanabe; Takumi Inami; Takahiro Hiraide; Kohtaro Abe; Yoshihiro Dohi; Yoshito Ogihara; Takeshi Ogo; Shiro Adachi; Kazuhiko Nakazato; Ichizo Tsujino; Hideki Ota; Kohei Komaru; Haruka Sato; Yuta Tezuka; Yoshikiyo Ono; Rika Suda; Kazuya Hosokawa; Sarasa Isobe; Takatoyo Kiko; Yuki Koga; Junichi Nakamura; Koichiro Sugimura; Masaru Hatano; Yoshihiro Fukumoto; Satoshi Yasuda
Pulmonary circulation, 15, 2, e70116, 2025年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Hypopituitarism has been reported in patients receiving continuous infusions of prostaglandin I2 (PGI2) analogues for pulmonary hypertension (PH). However, these patients' clinical characteristics, treatment, and prognoses remain unclear. This retrospective multicentre study included 22 patients who developed hypopituitarism while on continuous PGI2 analogue infusion between 1999 and 2021. All patients were female, and idiopathic pulmonary arterial hypertension was the most common underlying condition (63.6%). Their mean age was 38.8 ± 7.9 years. Epoprostenol was the predominant PGI2 analogue used (90.9%). At the time of hypopituitarism onset, the median PGI2 dose was 67.2 ng/kg/min (31.8-88.7 ng/kg/min), and the median treatment duration was 889.0 days (450.5-1941.5 days), suggesting that hypopituitarism occurred independent of its dose or treatment duration. Diagnoses were based on decreased adrenocorticotropic hormone levels. The hypopituitarism classification revealed isolated pituitary dysfunction in 54.5% of the cases, partial dysfunction in 18.1%, and complete dysfunction in 27.2%. Most cases could be managed without requiring specific therapies. After hypopituitarism onset, 63.6% of the patients continued to receive the same PGI2 analogue. Hydrocortisone therapy was administered to 81.8% of the patients, leading to clinical stabilisation. No deaths were reported. In conclusions, hypopituitarism may occur during continuous PGI2 analogue infusion for PH, irrespective of its dose or treatment duration. Initiating hydrocortisone therapy may be important for stabilising the clinical course. - Cancer as an independent mortality risk in chronic thromboembolic pulmonary hypertension.
Junichi Nakamura; Ichizo Tsujino; Kohei Masaki; Kazuya Hosokawa; Kouta Funakoshi; Yu Taniguchi; Shiro Adachi; Takumi Inami; Jun Yamashita; Hitoshi Ogino; Masaru Hatano; Nobuhiro Yaoita; Nobutaka Ikeda; Hiroto Shimokawahara; Nobuhiro Tanabe; Kayoko Kubota; Ayako Shigeta; Yoshito Ogihara; Koshin Horimoto; Yoshihiro Dohi; Takashi Kawakami; Yuichi Tamura; Koichiro Tatsumi; Kohtaro Abe
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 44, 3, 339, 348, 2025年03月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The management of chronic thromboembolic pulmonary hypertension (CTEPH) has advanced significantly in recent years, thereby improving patient prognosis. However, the impact of cancer on the outcomes of patients with CTEPH under current treatment remains unclear. This study aimed to investigate the prevalence of cancer in patients with CTEPH and determine how comorbid cancer affects their prognosis and clinical course. METHODS: Data from an ongoing Japanese prospective cohort study were analyzed. Prevalence and primary cancer sites were evaluated. The association of a history of cancer with a composite endpoint, including all-cause death, lung transplantation, and worsening of CTEPH, as well as venous thromboembolism and bleeding events, was assessed. RESULTS: Of the 1,270 patients in the cohort, 134 (10.6%) had a history of cancer, with the most common primary sites being the breast in women and the prostate in men. The incidence of composite outcome and all-cause death was higher in those with a history of cancer (p < 0.001, log-rank test). In the Cox proportional hazard model, age- and sex-adjusted hazard ratios for the composite outcome and all-cause death were 2.69 (95% confidence interval, 1.48-4.89, p = 0.001) and 4.25 (95% confidence interval, 1.98-9.10, p < 0.001), respectively, for patients with a history of cancer. No significant differences in venous thromboembolism and bleeding events were observed between patients with and those without a history of cancer. CONCLUSIONS: A history of cancer, with a prevalence of 10.6%, is an independent risk factor for mortality in patients with CTEPH undergoing the currently recommended treatment. - Prevalence, incidence, and clinical features of cardiac involvement in patients with pulmonary sarcoidosis.
Junichi Nakamura; Takahiro Sato; Hiroshi Ohira; Shuhei Yoshikawa; Takeshi Hattori; Osamu Manabe; Noriko Oyama-Manabe; Satonori Tsuneta; Hirokazu Kimura; Sakae Takenaka; Toshiyuki Nagai; Toshihisa Anzai; Masaharu Nishimura; Isao Yokota; Ichizo Tsujino; Satoshi Konnno
Respiratory medicine, 238, 107954, 107954, 2025年03月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The epidemiology and characteristics of cardiac involvement in patients with pulmonary sarcoidosis remain unclear. We aimed to determine the prevalence, incidence, and clinical features of cardiac sarcoidosis in patients with pulmonary sarcoidosis. METHODS: The characteristics of patients with biopsy-proven pulmonary sarcoidosis were retrospectively evaluated. Cardiac sarcoidosis was diagnosed via evaluations, including 18F-fluorodeoxyglucose positron emission tomography at the time of diagnosis of pulmonary sarcoidosis and during follow-up. Characteristics of patients with and without cardiac complications were compared. RESULTS: In total, 438 patients with pulmonary sarcoidosis were included, of which 40 (9.1 %) were diagnosed with cardiac sarcoidosis at the time of diagnosis of pulmonary sarcoidosis. During the follow-up period, 14 patients (4 %) developed cardiac complications (0.0075/person-years). Electrocardiographic abnormalities were the most common findings leading to the diagnosis of cardiac sarcoidosis (85 %). Compared to patients without cardiac involvement, those with cardiac sarcoidosis had lower serum angiotensin converting enzyme concentration [19.9 (15.5-25.1) vs. 17.4 (12.6-23.8) U/L)], higher rates of kidney complications (3 vs. 13 %), fewer ocular complications (78 vs. 17 %), and lower lymphocyte levels [35.8 (18.6-53) vs. 25.1 (14.2-38.2)%] and CD4/CD8 ratios [4.8 (3.1-7.5)% vs. 3.9 (1.8-6)%] in bronchoalveolar lavage fluid analysis. CONCLUSION: At the time of diagnosis of pulmonary sarcoidosis, cardiac complications occurred in approximately 10 % of the patients and developed in 0.0075/person-year during follow-up. Low serum angiotensin converting enzyme concentration, lymphocyte level and CD4/CD8 ratio in the bronchoalveolar lavage fluid may be unique features of patients with cardiac sarcoidosis. - Echocardiographic estimation of right ventricular diastolic stiffness based on pulmonary regurgitant velocity waveform analysis in precapillary pulmonary hypertension.
Yui Nagai; Michito Murayama; Sanae Kaga; Hideki Shima; Satonori Tsuneta; Shinobu Yokoyama; Hisao Nishino; Mana Goto; Yukino Suzuki; Yusuke Yanagi; Suguru Ishizaka; Hiroyuki Iwano; Junichi Nakamura; Takahiro Sato; Ichizo Tsujino
The international journal of cardiovascular imaging, 40, 5, 1123, 1134, 2024年05月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Right ventricular (RV) diastolic stiffness is an independent predictor of survival and is strongly associated with disease severity in patients with precapillary pulmonary hypertension (PH). Therefore, a fully validated echocardiographic method for assessing RV diastolic stiffness needs to be established. This study aimed to compare echocardiography-derived RV diastolic stiffness and invasively measured pressure-volume loop-derived RV diastolic stiffness in patients with precapillary PH. We studied 50 consecutive patients with suspected or confirmed precapillary PH who underwent cardiac catheterization, magnetic resonance imaging, and echocardiography within a 1-week interval. Single-beat RV pressure-volume analysis was performed to determine the gold standard for RV diastolic stiffness. Elevated RV end-diastolic pressure (RVEDP) was defined as RVEDP ≥ 8 mmHg. Using continuous-wave Doppler and M-mode echocardiography, an echocardiographic index of RV diastolic stiffness was calculated as the ratio of the atrial-systolic descent of the pulmonary artery-RV pressure gradient derived from pulmonary regurgitant velocity (PRPGDAC) to the tricuspid annular plane movement during atrial contraction (TAPMAC). PRPGDAC/TAPMAC showed significant correlation with β (r = 0.54, p < 0.001) and RVEDP (r = 0.61, p < 0.001). A cut-off value of 0.74 mmHg/mm for PRPGDAC/TAPMAC showed 83% sensitivity and 93% specificity for identifying elevated RVEDP. Multivariate analyses indicated that PRPGDAC/TAPMAC was independently associated with disease severity in patients with precapillary PH, including substantial PH symptoms, stroke volume index, right atrial size, and pressure. PRPGDAC/TAPMAC, based on pulmonary regurgitation velocity waveform analysis, is useful for the noninvasive assessment of RV diastolic stiffness and is associated with prognostic risk factors in precapillary PH. - Deep learning to assess right ventricular ejection fraction from two-dimensional echocardiograms in precapillary pulmonary hypertension.
Michito Murayama; Hiroyuki Sugimori; Takaaki Yoshimura; Sanae Kaga; Hideki Shima; Satonori Tsuneta; Aoi Mukai; Yui Nagai; Shinobu Yokoyama; Hisao Nishino; Junichi Nakamura; Takahiro Sato; Ichizo Tsujino
Echocardiography (Mount Kisco, N.Y.), 41, 4, e15812, 2024年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Precapillary pulmonary hypertension (PH) is characterized by a sustained increase in right ventricular (RV) afterload, impairing systolic function. Two-dimensional (2D) echocardiography is the most performed cardiac imaging tool to assess RV systolic function; however, an accurate evaluation requires expertise. We aimed to develop a fully automated deep learning (DL)-based tool to estimate the RV ejection fraction (RVEF) from 2D echocardiographic videos of apical four-chamber views in patients with precapillary PH. METHODS: We identified 85 patients with suspected precapillary PH who underwent cardiac magnetic resonance imaging (MRI) and echocardiography. The data was divided into training (80%) and testing (20%) datasets, and a regression model was constructed using 3D-ResNet50. Accuracy was assessed using five-fold cross validation. RESULTS: The DL model predicted the cardiac MRI-derived RVEF with a mean absolute error of 7.67%. The DL model identified severe RV systolic dysfunction (defined as cardiac MRI-derived RVEF < 37%) with an area under the curve (AUC) of .84, which was comparable to the AUC of RV fractional area change (FAC) and tricuspid annular plane systolic excursion (TAPSE) measured by experienced sonographers (.87 and .72, respectively). To detect mild RV systolic dysfunction (defined as RVEF ≤ 45%), the AUC from the DL-predicted RVEF also demonstrated a high discriminatory power of .87, comparable to that of FAC (.90), and significantly higher than that of TAPSE (.67). CONCLUSION: The fully automated DL-based tool using 2D echocardiography could accurately estimate RVEF and exhibited a diagnostic performance for RV systolic dysfunction comparable to that of human readers. - Exploratory analysis of the accuracy of echocardiographic parameters for the assessment of right ventricular function and right ventricular-pulmonary artery coupling.
Hideki Shima; Ichizo Tsujino; Junichi Nakamura; Toshitaka Nakaya; Ayako Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Satonori Tsuneta; Yasuyuki Chiba; Michito Murayama; Isao Yokota; Satoshi Konno
Pulmonary circulation, 14, 2, e12368, 2024年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Echocardiography is a widely used modality for the assessment of right ventricular (RV) function; however, few studies have comprehensively compared the accuracy of echocardiographic parameters using invasively obtained reference values. Therefore, this exploratory study aimed to compare the accuracy of echocardiographic parameters of RV function and RV-pulmonary artery (PA) coupling. We calculated four indices of RV function (end-systolic elastance [Ees] for systolic function [contractility], τ for relaxation, and β and end-diastolic elastance [Eed] for stiffness), and an index of RV-PA coupling (Ees/arterial elastance [Ea]), using pressure catheterization, cardiac magnetic resonance imaging, and a single-beat method. We then compared the correlations of RV indices with echocardiographic parameters. In 63 participants (54 with pulmonary hypertension (PH) and nine without PH), Ees and τ correlated with several echocardiographic parameters, such as RV diameter and area, but the correlations were moderate (|correlation coefficients (ρ)| < 0.5 for all parameters). The correlations of β and Eed with echocardiographic parameters were weak, with |ρ| < 0.4. In contrast, Ees/Ea closely correlated with RV free wall longitudinal strain (RVFW-LS)/estimated systolic PA pressure (eSPAP) (ρ = -0.72). Ees/Ea also correlated with tricuspid annular plane systolic excursion/eSPAP, RV diameter, and RV end-systolic area, with |ρ | >0.65. In addition, RVFW-LS/eSPAP yielded high sensitivity (0.84) and specificity (0.75) for detecting reduced Ees/Ea. The present study indicated a limited accuracy of echocardiographic parameters in assessing RV systolic and diastolic function. In contrast to RV function, they showed high accuracy for assessing RV-PA coupling, with RVFW-LS/eSPAP exhibiting the highest accuracy. - Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study.
Yugo Yamashita; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo
Annals of vascular diseases, 17, 1, 1, 8, 2024年03月25日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Objectives: The potential benefit of routine prophylactic anticoagulation for all hospitalized patients with clinically stable coronavirus disease 2019 (COVID-19) is still controversial. Method: The CLOT-COVID Study was a multicenter observational study enrolling 2894 consecutive hospitalized patients with COVID-19. The current study population consisted of 1738 hospitalized patients with mild COVID-19 at admission not requiring oxygen administration, who were divided into 2 groups: patients with prophylactic anticoagulation (n = 326) and those without (n = 1412). Results: Patients with prophylactic anticoagulation had more severe status of the worst severity of COVID-19 during hospitalization compared with those without (mild: 38% versus 82%, moderate: 55% versus 17%, and severe or death at discharge: 6.4% versus 0.7%, P <0.001). During hospitalization, 8 patients (0.5%) developed thrombosis, and the incidences of thrombosis were numerically higher in patients with more severe status of worst severity of COVID-19 during hospitalization (mild: 0.2%, moderate: 1.2%, and severe or death at discharge: 3.2%). Conclusions: Among hospitalized patients with clinically stable COVID-19 at admission, patients who did not worsen in COVID-19 severity after admission rarely developed thrombosis, although patients with worsening of COVID-19 severity after admission more often received prophylactic anticoagulation and might have a higher risk of thrombosis. - びまん性肺胞出血を呈したリンパ脈管筋腫症の一例
木村 太俊; 武井 望; 小熊 昂; 堀井 洋志; 中村 順一; 中久保 祥; 木村 孔一; 鈴木 雅; 大高 和人; 加藤 達哉; 大川 紘弥; 松野 吉宏; 今野 哲
日本呼吸器学会誌, 13, 増刊, 244, 244, (一社)日本呼吸器学会, 2024年03月
日本語 - 慢性血栓塞栓性肺高血圧症患者の有病率,管理,転帰に対する癌の影響
中村順一; 辻野一三; 辻野一三; 島秀起; 中谷資隆; 杉本絢子; 佐藤隆博; 佐藤隆博; 渡部拓; 大平洋; 鈴木雅; 横田勲; 今野哲; 今野哲
日本肺高血圧・肺循環学会学術集会抄録集(Web), 9th (CD-ROM), 4, 588, 593, 2024年, [国際誌]
英語, INTRODUCTION: Chronic thromboembolic pulmonary hypertension (CTEPH) results from unresolved thrombotic obstruction of the pulmonary vasculature. Cancer is a known risk factor for CTEPH. This study aimed to determine the impact of cancer on the prevalence, management, and outcomes of patients with CTEPH. MATERIALS AND METHODS: In this retrospective study involving 99 patients sequentially diagnosed with CTEPH in our hospital, the prevalence of 10 comorbid conditions including a past history of cancer at the time of CTEPH diagnosis were calculated. RESULTS: Among the 99 patients, 17 (17%) had a history of cancer. Breast cancer (n = 6) was the most common cancer type, followed by gastrointestinal cancer (n = 3), uterine cancer (n = 2), and malignant lymphoma (n = 2). Between patients with and without cancer, there were no differences in the demographics, severity of CTEPH, and management; however, the 5-year survival rate was lower for patients with cancer (65%) than for those without (89%). In addition, patients with cancer had significantly worse survival than those without (p = 0.03 by log-rank test). During follow-up, nine patients developed cancer after the diagnosis of CTEPH. Among the 99 patients, 13 died during follow-up, 6 (46%) of whom died of cancer. CONCLUSIONS: 17% of our patients with CETPH were diagnosed with cancer, with breast and gastrointestinal tract cancers being the most common. Cancer comorbidity was associated with a poor prognosis and contributed to death in 46% of deceased patients. The impact of cancer on CTEPH should be further evaluated in the future. - Clinical Features Comparing Arterial Thrombosis and Venous Thromboembolism in Hospitalized Patients with COVID-19: Result from the CLOT-COVID Study.
Michihisa Umetsu; Hajime Kanamori; Koji Murakami; Takuya Shiga; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
Annals of vascular diseases, 16, 2, 115, 123, 2023年06月25日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Objectives: This study aimed to investigate the clinical features of arterial thrombosis and venous thromboembolism (VTE) in coronavirus disease 2019 (COVID-19). Methods: The CLOT-COVID Study was a retrospective, multicenter cohort study that enrolled 2,894 consecutively hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We compared the clinical features of arterial thrombosis and VTE. Results: Thrombosis was observed in 55 patients (1.9%) during hospitalization. Arterial thrombosis and VTE occurred in 12 (0.4%) and 36 (1.2%) patients, respectively. Among the 12 patients with arterial thrombosis, 9 (75%), 2 (17%), and 1 developed ischemic cerebral infarction, myocardial infarction, and acute limb ischemia, respectively, and there were five patients (42%) without comorbidities. Among 36 patients with VTE, 19 (53%) and 17 (47%) developed pulmonary embolism (PE) and deep vein thrombosis (DVT), respectively. PE was common in the early stages of hospitalization; whereas, DVT was common beyond the early stages of hospitalization. Conclusion: Among patients with COVID-19, arterial thrombosis was less common than VTE, although ischemic cerebral infarction seemed to be relatively common, and a certain number of patients developed arterial thrombosis even in the absence of known atherosclerosis risk factors. - Significant Impact of Age on Mortality and Non-significant Impact of Age on Thrombosis and Major Bleeding in Patients with COVID-19: From the CLOT-COVID Study.
Yugo Yamashita; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo
Journal of atherosclerosis and thrombosis, 30, 6, 624, 635, 2023年06月01日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), AIM: There is scarce data on the impact of age on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). METHOD: The CLOT-COVID Study was a retrospective, multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We divided the entire cohort into five groups according to age strata; -19, 20-39, 40-59, 60-79, and 80- years. RESULTS: Most patients under 19 had mild COVID-19 on admission (99%), while older patients had more severe COVID-19. The incidence rates of clinical outcomes during hospitalization in patients aged ≤ 19, 20-39, 40-59, 60-79, and 80 ≥ years were 0.0%, 0.5%, 2.2%, 2.7%, and 1.5% for thrombosis; 0.0%, 1.2%, 1.5%, 3.4%, and 2.0% for major bleeding; and 0.0%, 0.4%, 2.0%, 12.1%, and 16.8% for all-cause death, respectively. In the stratified analysis according to COVID-19 severity on admission, the incidences of thrombosis were generally higher among patients with more severe status, although those were not significantly different among age strata in all sub-types of COVID-19 severity. However, the incidences of all-cause death were significantly higher with increasing age in all sub-types of COVID-19 severity. CONCLUSIONS: In the current large observational study of patients with COVID-19, the risk of mortality became markedly higher with increased age. However, the risks of thrombosis and major bleeding did not necessarily increase as age increases, which seemed to be consistent irrespective of COVID-19 severity on admission. - Clinical and Hemodynamic Responses to Imatinib in Pulmonary Veno-Occlusive Disease/Pulmonary Capillary Hemangiomatosis: A Retrospective Pilot Study of Five Cases and Review of the Literature.
Junichi Nakamura; Ichizo Tsujino; Hideki Shima; Toshitaka Nakaya; Ayako Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Satonori Tsuneta; Ryo Hisada; Masaru Kato; Satoshi Konno
American journal of cardiovascular drugs : drugs, devices, and other interventions, 23, 3, 329, 338, 2023年05月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare types of pulmonary arterial hypertension with dismal prognoses; there is no established medical treatment for these conditions. Possible efficacy of imatinib against these conditions has been reported in 15 cases; however, how and in whom imatinib is effective remain unknown. METHODS: We retrospectively evaluated clinical data from consecutive patients with PVOD/PCH treated with imatinib at our institution. The diagnosis of PVOD/PCH was established using the following criteria: pre-capillary pulmonary hypertension; diffusion capacity of the lung for carbon monoxide < 60%; and two or more high-resolution computed tomography findings of interlobular septal thickening, centrilobular opacities, and mediastinal lymphadenopathy. The dose of pulmonary vasodilators remained unchanged during the assessment of imatinib. RESULTS: The medical records of five patients with PVOD/PCH were reviewed. The patients were aged 67 ± 13 years, their diffusion capacity of the lung for carbon monoxide was 29 ± 8%, and their mean pulmonary artery pressure was 40 ± 7 mmHg. Imatinib was administered at 50-100 mg/day; consequently, the World Health Organization functional class improved in one patient. In addition, imatinib improved the arterial oxygen partial pressure in this and another patient (these two also experienced a decreased mean pulmonary artery pressure and pulmonary vascular resistance after imatinib usage). CONCLUSIONS: This study indicated that imatinib improves the clinical condition, including pulmonary hemodynamics, of some patients with PVOD/PCH. In addition, patients with a certain high-resolution computed tomography pattern or PCH-dominant vasculopathy may respond favorably to imatinib. - Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study.
Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita; On Behalf Of The Clot-Covid Study Investigators
Annals of vascular diseases, 16, 1, 31, 37, 2023年03月25日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Objectives: The relationship between the thrombotic event and prognosis in patients with coronavirus disease 2019 (COVID-19) has not yet been fully investigated in Japan. Our study aimed to investigate the clinical outcomes and risk factors for thrombosis in hospitalized patients with COVID-19 in Japan. Materials and Methods: We compared the patient characteristics and clinical outcomes among patients with thrombosis (N=55) and those without thrombosis (N=2839) by using a large-scale data of CLOT-COVID study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800). Thrombosis included venous thromboembolism, ischemic stroke, myocardial infarction, and systemic arterial thromboembolism. Results: Higher rates of mortality and bleeding events were shown in hospitalized patients with COVID-19 with thrombosis compared to those without thrombosis (all-cause mortality, 23.6% vs. 5.1%, P<0.001; major bleeding, 23.6% vs. 1.6%, P<0.001). Multivariable analysis revealed that the independent risk factors of thrombosis were male sex, D-dimer level on admission>1.0 µg/mL, and moderate and severe COVID-19 status on admission. Conclusions: The development of thrombosis in hospitalized patients with COVID-19 was related to higher mortality and major bleeding, and several independent risk factors for thrombosis could help determine the patient-appropriate treatment for COVID-19. - Mortality-associated Risk Factors in Hospitalized COVID-19 Patients in Japan: Findings of the CLOT-COVID Study.
Makoto Takeyama; Sen Yachi; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
Journal of epidemiology, 33, 3, 150, 157, 2023年03月05日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Reports of mortality-associated risk factors in patients with the novel coronavirus disease 2019 (COVID-19) are limited. METHODS: We evaluated the clinical features that were associated with mortality among patients who died during hospitalization (n = 158) and those who were alive at discharge (n = 2,736) from the large-scale, multicenter, retrospective, observational cohort CLOT-COVID study, which enrolled consecutively hospitalized COVID-19 patients from 16 centers in Japan from April to September 2021. Data from 2,894 hospitalized COVID-19 participants of the CLOT-COVID study were analyzed in this study. RESULTS: Patients who died were older (71.1 years vs 51.6 years, P < 0.001), had higher median D-dimer values on admission (1.7 µg/mL vs 0.8 µg/mL, P < 0.001), and had more comorbidities. On admission, the patients who died had more severe COVID-19 than did those who survived (mild: 16% vs 63%, moderate: 47% vs 31%, and severe: 37% vs 6.2%, P < 0.001). In patients who died, the incidence of thrombosis and major bleeding during hospitalization was significantly higher than that in those who survived (thrombosis: 8.2% vs 1.5%, P < 0.001; major bleeding: 12.7% vs 1.4%, P < 0.001). Multivariable logistic regression analysis revealed that age >70 years, high D-dimer values on admission, heart disease, active cancer, higher COVID-19 severity on admission, and development of major bleeding during hospitalization were independently associated with a higher mortality risk. CONCLUSION: This large-scale observational study in Japan identified several independent risk factors for mortality in hospitalized patients with COVID-19 that could facilitate appropriate risk stratification of patients with COVID-19. - An Adult Case of Unilateral Left Pulmonary Artery Agenesis Presenting with Hemoptysis.
Yuriko Ishida; Masaru Suzuki; Hiroshi Horii; Junichi Nakamura; Munehiro Matsumoto; Sho Nakakubo; Takahiro Sato; Ichizo Tsujino; Ryo Morita; Daisuke Abo; Satoshi Konno
Internal medicine (Tokyo, Japan), 62, 5, 763, 767, 2023年03月01日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Pulmonary artery agenesis (PAA) is a rare congenital vascular anomaly usually diagnosed during infancy. We herein report a 67-year-old man with PAA manifesting as massive hemoptysis. Contrast-enhanced computed tomography of the chest revealed the diagnosis of PAA, which we speculated to have resulted in the present event. Detailed angiography provided more accurate information on the pulmonary vasculature and collateral circulation, which helped us plan tailored treatment. Although very rare, we must consider the possibility of PAA in adults with unexplained hemoptysis. - Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admission - From the CLOT-COVID Study.
Satoshi Ikeda; Yuki Ueno; Koji Maemura; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
Circulation journal : official journal of the Japanese Circulation Society, 87, 3, 448, 455, 2023年02月24日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: The worsening of coronavirus disease 2019 (COVID-19) severity is a critical issue in current clinical settings and may be associated with the development of thrombosis.Methods and Results: This study used patient data obtained in the CLOT-COVID study, a retrospective multicenter cohort study. The demographics of patients with moderate COVID-19 on admission with and without worsened severity during hospitalization were compared and predictors were identified. Of 927 patients with moderate COVID-19 on admission, 182 (19.6%) had worsened severity during hospitalization. Patients with worsening of severity were older, more likely to have hypertension, diabetes, heart disease, and active cancer, and more likely to use pharmacological thromboprophylaxis. Patients with worsening of severity had higher D-dimer levels on admission and were more likely to develop thrombosis and major bleeding during hospitalization than those without worsening. Increased age (odds ratio [OR]: 1.02, 95% confidence interval [CI]: 1.01-1.03, P=0.005), diabetes (OR: 1.63, 95% CI: 1.11-2.33, P=0.012), D-dimer levels >1.0 μg/mL on admission (OR: 2.10, 95% CI: 1.45-3.03, P<0.001), and thrombosis (OR: 6.28, 95% CI: 2.72-14.53, P<0.001) were independently associated with worsening of COVID-19 severity. CONCLUSIONS: Approximately 20% of patients with moderate COVID-19 had worsened severity during hospitalization. Increased age, diabetes, D-dimer levels >1.0 μg/mL on admission, and the development of thrombosis during hospitalization were significantly associated with worsened COVID-19 severity. - Influence of obesity on incidence of thrombosis and disease severity in patients with COVID-19: From the CLOT-COVID study.
Yoshito Ogihara; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
Journal of cardiology, 81, 1, 105, 110, 2023年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The influence of obesity on the development of thrombosis and severity of coronavirus disease 2019 (COVID-19) remains unclear. METHOD: The CLOT-COVID study was a retrospective multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 between April 2021 and September 2021 among 16 centers in Japan. The present study consisted of 2690 patients aged over 18 years with available body mass index (BMI), who were divided into an obesity group (BMI ≥30) (N = 457) and a non-obesity group (BMI <30) (N = 2233). RESULTS: The obesity group showed more severe status of COVID-19 at admission compared with the non-obesity group. The incidence of thrombosis was not significantly different between the groups (obesity group: 2.6 % versus non-obesity group: 1.9 %, p = 0.39), while the incidence of a composite outcome of all-cause death, or requirement of mechanical ventilation or extracorporeal membrane oxygenation during hospitalization was significantly higher in the obesity group (20.1 % versus 15.0 %, p < 0.01). After adjusting confounders in the multivariable logistic regression model, the risk of obesity relative to non-obesity for thrombosis was not significant (adjusted OR, 1.39; 95 % CI, 0.68-2.84, p = 0.37), while the adjusted risk of obesity relative to non-obesity for the composite outcome was significant (adjusted OR, 1.85; 95 % CI, 1.39-2.47, p < 0.001). CONCLUSIONS: In the present large-scale observational study, obesity was not significantly associated with the development of thrombosis during hospitalization; however, it was associated with severity of COVID-19. - Pulmonary arterial hypertension in an 80-year-old man with long-term use of cyclophosphamide.
Takatoshi Suzuki; Ichizo Tsujino; Wataru Harabayashi; Hideki Shima; Junichi Nakamura; Takahiro Sato; Masaru Suzuki; Yukari Takeda; Satohi Konno
Respiratory medicine case reports, 44, 101867, 101867, 2023年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), An 80-year-old man diagnosed with primary macroglobulinemia 7 years earlier had been treated with cyclophosphamide, following which he developed dyspnea on exertion. Cyclophosphamide was discontinued. The patient's dyspnea, however, failed to improve. Right heart catheterization (RHC) revealed precapillary pulmonary hypertension (PH). He was transferred to our institution for further examination. Prior use of cyclophosphamide was the patient's only risk factor for PH, and cyclophosphamide use was considered as a possible cause of PH in this case. He was treated with tadalafil and dyspnea gradually improved. A follow-up RHC exhibited improvement in mean pulmonary arterial pressure and pulmonary vascular resistance. - Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
Yuichi Kojima; Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Nozomu Takei; Junichi Nakamura; Munehiro Matsumoto; Hiroshi Horii; Kazuki Sato; Hideki Shima; Masaru Suzuki; Satoshi Konno
Journal of medical virology, 94, 12, 5702, 5712, 2022年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Immunomodulators (tocilizumab/baricitinib) improve outcomes of coronavirus disease 2019 (COVID-19) patients, but the synergistic effect of remdesivir is unknown. The effect of combination therapy with remdesivir, immunomodulators, and standard treatment in COVID-19 patients was investigated. This retrospective, single-center study included COVID-19 patients who were treated with tocilizumab or baricitinib. The severity of respiratory status in the two groups on Days 14 and 28 and the duration to respiratory recovery in both groups were compared, and the effect of remdesivir use on respiratory status was examined in a multivariate analysis. Ninety-eight patients received tocilizumab or baricitinib; among them, 72 used remdesivir (remdesivir group) and 26 did not (control group). The remdesivir group achieved faster respiratory recovery than the control group (median 11 vs. 21 days, p = 0.033), faster weaning from supplemental oxygen (hazard ratio [HR]: 2.54, 95% confidence interval [CI]: 1.14-5.66, p = 0.021). Age, body mass index, diabetes mellitus, and time from onset to oxygen administration were independent prognostic factors. The remdesivir group achieved better severity level at Days 14 and 28 (p = 0.033 and 0.003, respectively) and greater improvement from baseline severity (p = 0.047 and 0.018, respectively). Remdesivir combination therapy did not prolong survival (HR: 0.31, 95% CI: 0.04-2.16, p = 0.23). Among severely ill COVID-19 patients who received immunomodulator, remdesivir contributed to a shorter respiratory recovery time and better respiratory status at Days 14 and 28. Concomitant remdesivir with immunomodulators and standard treatment may provide additional benefit in improving respiratory status of COVID-19 patients. - Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan: From the CLOT-COVID Study.
Hiroya Hayashi; Yasuhiro Izumiya; Daiju Fukuda; Fumiaki Wakita; Yasumitsu Mizobata; Hiromichi Fujii; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
JACC. Asia, 2, 7, 897, 907, 2022年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Data on prophylactic anticoagulation are important in understanding the current issues, unmet needs, and optimal management of Japanese COVID-19 patients. OBJECTIVES: This study aimed to investigate the clinical management strategies for prophylactic anticoagulation of COVID-19 patients in Japan. METHODS: The CLOT-COVID study was a multicenter observational study that enrolled 2,894 consecutive hospitalized patients with COVID-19. The study population consisted of 2,889 patients (after excluding 5 patients with missing data); it was divided into 2 groups: patients with pharmacological thromboprophylaxis (n = 1,240) and those without (n = 1,649). Furthermore, we evaluated the 1,233 patients who received prophylactic anticoagulation-excluding 7 patients who could not be classified based on the intensity of their anticoagulants-who were then divided into 2 groups: patients receiving prophylactic anticoagulant doses (n = 889) and therapeutic anticoagulant doses (n = 344). RESULTS: The most common pharmacological thromboprophylaxis anticoagulant was unfractionated heparin (68.2%). The severity of COVID-19 at admission was a predictor of the implementation of pharmacological thromboprophylaxis in the multivariable analysis (moderate vs mild: OR: 16.6; 95% CI:13.2-21.0; P < 0.001, severe vs mild: OR: 342.6, 95% CI: 107.7-1090.2; P < 0.001). It was also a predictor of the usage of anticoagulants of therapeutic doses in the multivariable analysis (moderate vs mild: OR: 2.10; 95% CI: 1.46-3.02; P < 0.001, severe vs mild: OR: 5.96; 95% CI: 3.91-9.09; P < 0.001). CONCLUSIONS: In the current real-world Japanese registry, pharmacological thromboprophylaxis, especially anticoagulants at therapeutic doses, was selectively implemented in COVID-19 patients with comorbidities and severe COVID-19 status at admission. - Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension.
Yuta Takashima; Naofumi Shinagawa; Daisuke Morinaga; Junichi Nakamura; Megumi Furuta; Tetsuaki Shoji; Hajime Asahina; Eiki Kikuchi; Junko Kikuchi; Jun Sakakibara-Konishi; Ichizo Tsujino; Satoshi Konno
BMC pulmonary medicine, 22, 1, 449, 449, 2022年11月28日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Endobronchial ultrasound (EBUS)-guided transbronchial biopsy (TBB) facilitates the diagnosis of various respiratory diseases. The safety of performing EBUS-guided TBB in patients with a finding of pulmonary hypertension (PH) is controversial. Little is known about the relationship between the risk of bleeding associated with EBUS-guided TBB in the presence of PH suspected on echocardiography or chest CT. METHODS: To assess the risk of bleeding associated with EBUS-guided TBB in patients with presumed PH per echocardiography or chest CT, we retrospectively reviewed the medical records of 314 consecutive patients who underwent EBUS-guided TBB using a guide sheath (GS), as well as echocardiography and chest CT. Bleeding complication was defined as over one minute of suctioning; repeated wedging of the bronchoscope; instillation of cold saline, diluted vasoactive substances, or thrombin due to persistent bleeding. Findings of suspected PH were defined as peak tricuspid regurgitation velocity (TRV) > 2.8 m/s on echocardiography or pulmonary artery to aorta ratio (PA:A ratio) > 0.9 on chest CT. RESULTS: In total, 35 (11.1%) patients developed bleeding, and all cases were managed safely. Furthermore, 17 (5.4%) and 59 (18.8%) patients were suspected to have PH based on echocardiography and chest CT, respectively. Among the patients suspected to have PH on echocardiography, five (5/17 = 29.4%) patients developed bleeding. Among the patients suspected to have PH on chest CT, 11 (11/59 = 18.6%) patients developed bleeding. Univariate analysis revealed that long diameter (≥ 30 mm) of the lesion, lesion location (the biopsy site was inner than the segmental bronchus), bronchoscopic diagnosis of malignancy, and additional biopsy were potential predictive factors for bleeding. The finding of suspected PH on echocardiography correlated significantly with bleeding (p = 0.03). On multivariate analysis, long diameter (≥ 30 mm) of the lesion (p = .021) and findings of suspected PH on echocardiography (p = .049) were significantly associated with bleeding. CONCLUSION: All cases of bleeding in the present study were managed safely. The risk of bleeding is moderately elevated when PH is suspected by echocardiography in patients undergoing EBUS-guided TBB using a GS. - The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study.
Yuji Nishimoto; Sen Yachi; Makoto Takeyama; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
Journal of cardiology, 80, 4, 285, 291, 2022年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Data on thrombosis and current real-world management strategies for anticoagulation therapy are scarce but important for understanding current issues and unmet needs of an optimal management of patients with coronavirus disease 2019 (COVID-19). METHOD: The CLOT-COVID Study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800) was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021, and we tried to capture the status of the patients in the fourth and fifth waves of the COVID-19 infections in Japan. We enrolled consecutive hospitalized patients who were diagnosed with COVID-19 and had a positive polymerase chain reaction test obtained from the hospital databases. RESULTS: Among 2894 patients with COVID-19, 1245 (43%) received pharmacological thromboprophylaxis. The proportion of pharmacological thromboprophylaxis increased according to the severity of the COVID-19 in 9.8% with mild COVID-19, 61% with moderate COVID-19, and 97% with severe COVID-19. The types and doses of anticoagulants varied widely across the participating centers. During the hospitalization, 38 patients (1.3%) and 126 (4.4%) underwent ultrasound examinations for the lower extremities and contrast-enhanced computed tomography examinations, respectively, and 55 (1.9%) developed thrombosis, mostly venous thromboembolism (71%). The incidence of thrombosis increased according to the severity of the COVID-19 in 0.2% with mild COVID-19, 1.4% with moderate COVID-19, and 9.5% with severe COVID-19. Major bleeding occurred in 57 patients (2.0%) and 158 (5.5%) died, and 81% of them were due to respiratory failure from COVID-19 pneumonia. CONCLUSIONS: In the present large-scale observational study, pharmacological thromboprophylaxis for hospitalized patients with COVID-19 was common especially in patients with severe COVID-19, and management strategies varied widely across the participating centers. The overall incidence of thrombosis was substantially low with an increased incidence according to the severity of the COVID-19. - Efficacy and safety of oral pulmonary vasodilators in pulmonary veno-occlusive disease.
Junichi Nakamura; Ichizo Tsujino; Hideki Shima; Toshitaka Nakaya; Ayako Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Satonori Tsuneta; Ryo Hisada; Masaru Kato; Satoshi Konno
Pulmonary circulation, 12, 4, e12168, 2022年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH) is a rare subtype of pulmonary hypertension with dismal prognosis. Limited data are available on the efficacy and safety of orally administered pulmonary vasodilators for PVOD/PCH. Whether and how systemic sclerosis (SSc) affects the clinical outcomes of PVOD/PCH is also unknown. This study aimed to determine the clinical and hemodynamic efficacy and safety of oral pulmonary vasodilators for PVOD/PCH and clarify the possible effects of SSc on the clinical presentation of PVOD/PCH. We retrospectively analyzed the clinical data of 15 patients with PVOD/PCH treated with oral pulmonary vasodilators in our department since 2001. Six of them had SSc. Oral pulmonary vasodilators were administered either as single agents (n = 10) or in combination (n = 5). Treatment improved the functional class of five patients, and pulmonary arterial pressure and pulmonary vascular resistance decreased by 10 ± 12 mmHg and 36 ± 19%, respectively (p < 0.05 for both, n = 13), whereas pulmonary edema developed in three patients. The mean survival was 3.9 years, and the 1- and 3-year survival rates were 93% and 65%, respectively. The clinical presentation, including survival, was similar between patients with and without SSc. In our PVOD/PCH cohort, oral pulmonary vasodilators caused pulmonary edema in 20% of patients, but more than 80% of patients experienced significant pulmonary vasodilatory effects, and the overall prognosis was better than that previously reported. SSc does not adversely affect the clinical outcomes of PVOD/PCH. - Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study.
Junichi Nakamura; Ichizo Tsujino; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Satoshi Konno; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
Thrombosis journal, 20, 1, 53, 53, 2022年09月20日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and a potential benefit of anticoagulation therapy has been documented for prevention of thromboembolic events. Bleeding events has also been reported as a notable complication; whereas, the incidence, risks, and clinical impact of bleeding remain unclear. METHOD: The CLOT-COVID Study was a nationwide, retrospective, multicenter cohort study on consecutive hospitalized patients with COVID-19 in Japan between April 2021 and September 2021. In this sub-analysis, we compared the characteristics of patients with and without major bleeding; moreover, we examined the risk factors for and clinical impact of bleeding events. RESULTS: Among 2882 patients with COVID-19, 57 (2.0%) had major bleeding. The incidence of major bleeding increased with COVID-19 severity as follows: 0.5%, 2.3%, and 12.3% in patients with mild, moderate, and severe COVID-19, respectively. COVID-19 severity, history of major bleeding, and anticoagulant type/dose were independently and additively associated with the bleeding incidence. Compared with patients without major bleeding, those with major bleeding exhibited a longer duration of hospitalization (9 [6-14] vs 28 [19-43] days, P < 0.001) and higher mortality during hospitalization (4.9% vs. 35.1%, P < 0.001). CONCLUSIONS: In the real-world clinical practice, the incidence of major bleeding was not uncommon, especially in patients with severe COVID-19. Independent risk factors for major bleeding included history of major bleeding, COVID-19 severity, and anticoagulant use, which could be associated with poor clinical outcomes including higher mortality. Precise recognition of the risks for bleeding may be helpful for an optimal use of anticoagulants and for better outcomes in patients with COVID-19. - Various factors contribute to death in patients with different types of pulmonary hypertension: A retrospective pilot study from a single tertiary center.
Junichi Nakamura; Ichizo Tsujino; Hiroshi Ohira; Toshitaka Nakaya; Ayako Sugimoto; Takahiro Sato; Taku Watanabe; Masaru Suzuki; Masaru Kato; Isao Yokota; Satoshi Konno
Respiratory investigation, 60, 5, 647, 657, 2022年09月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: A few studies have focused on the cause of death from different types of pulmonary hypertension (PH). This study aimed to systematically analyze the primary and secondary causes of death and compare the profiles between different PH groups. METHODS: The contribution of PH to death was assessed in precapillary PH (i.e., group 1 [pulmonary arterial hypertension], group 3 [PH associated with lung disease], and group 4 [chronic thromboembolic PH]) using specific criteria; death was classified into three categories: PH death (death due to PH only), PH-related death, and PH-unrelated death. Disorders other than PH that contributed to death were analyzed, and mortality profiles were compared between groups. RESULTS: Eighty deceased patients with PH were examined (group 1, n = 28; group 3, n = 39; and group 4, n = 13). The contribution of PH to death was significantly different between the three groups. "PH death" was most common in group 1 (61%), "PH-related death" in group 3 (56%), and "PH-related death" and "PH-unrelated death" in group 4 (38% for both). The highest contributing factor to death other than PH was respiratory failure in group 3 and malignant disease in group 4. CONCLUSIONS: Significant variations in the causes of death were observed in groups 1, 3, and 4 PH patients. In addition to PH, respiratory failure and malignant disease significantly contributed to death in group 3 and group 4 PH, respectively. Understanding the precise death cause may be important in achieving better outcomes in PH patients. - Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study.
Yugo Yamashita; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo
Circulation journal : official journal of the Japanese Circulation Society, 86, 7, 1137, 1142, 2022年06月24日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: The potential benefit of therapeutic-dose anticoagulation for critically ill patients with coronavirus disease 2019 (COVID-19) is still controversial.Methods and Results: In the CLOT-COVID study, 225 patients with severe COVID-19 on admission requiring mechanical ventilation or extracorporeal membrane oxygenation were divided into patients with therapeutic-dose anticoagulation (N=110) and those with prophylactic-dose anticoagulation (N=115). There was no significant difference in the incidence of thrombosis between the groups (9.1% vs. 7.8%, P=0.73). CONCLUSIONS: Among a cohort of critically ill patients with COVID-19, approximately half received therapeutic-dose anticoagulation, although it did not show a potential benefit compared with prophylactic-dose anticoagulation. - 静脈および動脈血栓症の分析 CLOT-COVID Studyより
梅津 道久; 山下 侑吾; 谷地 繊; 竹山 誠; 西本 裕二; 辻野 一三; 中村 順一; 山本 尚人; 中田 弘子; 池田 聡司; 相川 志都; 林 浩也; 佐戸川 弘之; 奥野 善教; 岩田 英理子; 荻原 義人; 池田 長生; 近藤 朱音; 岩井 武尚; 山田 典一; 小川 智弘; 小林 隆夫; 孟 真
静脈学, 33, 2, 147, 147, (一社)日本静脈学会, 2022年06月
日本語 - CLOT-COVID studyにおける大出血例の検討
中村 順一; 辻野 一三; 児島 裕一; 島 秀起; 中久保 祥; 今野 哲
静脈学, 33, 2, 146, 146, (一社)日本静脈学会, 2022年06月
日本語 - D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan - From the CLOT-COVID Study.
Nobutaka Ikeda; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo; Yugo Yamashita
Circulation reports, 4, 5, 215, 221, 2022年05月10日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Background: To date, there are no large-scale data on the association between D-dimer levels at admission and the occurrence of venous thromboembolism (VTE) in Japanese patients with coronavirus disease 2019 (COVID-19). Methods and Results: The CLOT-COVID study was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 across 16 centers in Japan from April 2021 to September 2021. Among 2,894 enrolled patients, 2,771 (96%) had D-dimer levels measured at admission. Patients were divided into 3 groups based on tertiles of D-dimer levels at admission (1st tertile, D-dimer ≤0.5 μg/mL, n=949; 2nd tertile, D-dimer 0.51-1.09 μg/mL, n=894; 3rd tertile, D-dimer ≥1.1 μg/mL, n=928). The higher the tertile group, the more severe the COVID-19 status at admission. The incidence of VTE during hospitalization was highest in the 3rd tertile group (1st tertile, 0.3%; 2nd tertile, 0.3%; 3rd tertile, 3.6%; P<0.001). Even after adjusting for confounders in the multivariable logistic regression model, the higher D-dimer levels in the 3rd tertile (≥1.1 μg/mL) were independently associated with a higher risk of VTE during hospitalization (adjusted odds ratio 4.83 [95% confidence interval 1.93-12.11; P<0.001]; reference=1st tertile). Conclusions: Higher D-dimer levels at admission were associated with a higher risk of VTE events during hospitalization in Japanese patients with COVID-19. This could be helpful in determining patient-specific anticoagulation management strategies for COVID-19 in Japan. - 今月の症例 両側滲出性胸水と全身浮腫で発症し、局所麻酔下胸腔鏡でサルコイドーシスと診断した1例
篠崎 鮎香[臺]; 木村 孔一; 山下 優; 堀井 洋志; 佐藤 一紀; 中村 順一; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 中里 信一; 松野 吉宏; 今野 哲
日本内科学会雑誌, 111, 5, 984, 989, (一社)日本内科学会, 2022年05月, [査読有り]
日本語 - 今月の症例 両側滲出性胸水と全身浮腫で発症し、局所麻酔下胸腔鏡でサルコイドーシスと診断した1例
篠崎 鮎香[臺]; 木村 孔一; 山下 優; 堀井 洋志; 佐藤 一紀; 中村 順一; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 中里 信一; 松野 吉宏; 今野 哲
日本内科学会雑誌, 111, 5, 984, 989, (一社)日本内科学会, 2022年05月
日本語, 66歳男性。全身倦怠感、全身浮腫を主訴に、前医にて両側滲出性胸水を指摘され、精査目的に当科紹介入院となった。血液検査や画像検査、胸水検査では特異的所見を認めず、局所麻酔下の胸腔鏡検査にて胸膜に多発結節性病変を認め、病理組織像および気管支鏡検査所見より、サルコイドーシス(組織診断群)と診断された。経過中に眼症状は認めず、プレドニゾロンによる内服治療を開始したところ、全身浮腫や両側胸水は改善傾向にあった。 - Delayed-onset Organizing Pneumonia Emerging after Recovery from Coronavirus Disease 2019: A Report of Three Cases Diagnosed Using Transbronchial Cryobiopsy and a Review of the Literature.
Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Junichi Nakamura; Munehiro Matsumoto; Hiroshi Horii; Kazuki Sato; Daisuke Morinaga; Masaru Suzuki; Nanase Okazaki; Emi Takakuwa; Yoshihiro Matsuno; Satoshi Konno
Internal medicine (Tokyo, Japan), 61, 9, 1403, 1410, 2022年05月01日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), We present three cases with an atypical clinical course of organizing pneumonia (OP) secondary to coronavirus disease 2019 (COVID-19). Three patients were discharged with satisfactory improvement after standard steroid therapy for COVID-19. Shortly after the completion of treatment, the patients experienced a flare-up of symptoms. Imaging results showed new lesions in the lungs. Transbronchial lung cryobiopsy showed histological findings consistent with OP in all cases. Steroids were administered, and a good therapeutic response was observed. This report is the first to describe pathologically confirmed OP that developed after recovery from COVID-19. Careful follow-up is advisable for patients who have recovered from COVID-19. - Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study.
Yugo Yamashita; Sen Yachi; Makoto Takeyama; Yuji Nishimoto; Ichizo Tsujino; Junichi Nakamura; Naoto Yamamoto; Hiroko Nakata; Satoshi Ikeda; Michihisa Umetsu; Shizu Aikawa; Hiroya Hayashi; Hirono Satokawa; Yoshinori Okuno; Eriko Iwata; Yoshito Ogihara; Nobutaka Ikeda; Akane Kondo; Takehisa Iwai; Norikazu Yamada; Tomohiro Ogawa; Takao Kobayashi; Makoto Mo
Thrombosis research, 213, 173, 178, 2022年05月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: There has been limited data on the influence of sex on development of thrombosis in patients with coronavirus disease 2019 (COVID-19). MATERIALS AND METHODS: The CLOT-COVID Study was a retrospective, multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We divided the entire cohort into the men (N = 1885) and women (N = 1009) groups. RESULTS: There were no significant differences in D-dimer levels at admission between men and women. Men had more severe status of the COVID-19 at admission compared with women (Mild: 57% versus 66%, Moderate: 34% versus 29%, and Severe: 9.1% versus 5.7%, P < 0.001). Men more often received pharmacological thromboprophylaxis than women (47% versus 35%, P < 0.001). During the hospitalization, men more often developed thrombosis than women (2.5% [95%CI, 1.9-3.3%] versus 0.8% [95%CI, 0.4-1.6%], P = 0.001). Men had numerically higher incidences of thrombosis than women in all subgroups of the worst severity of COVID-19 during the hospitalization (Mild: 0.3% versus 0.0%, Moderate: 1.6% versus 1.0%, and Severe: 11.1% versus 4.3%). Even after adjusting confounders in the multivariable logistic regression model, the excess risk of men relative to women remained significant for thrombosis (adjusted OR, 2.51; 95%CI, 1.16-5.43, P = 0.02). CONCLUSIONS: In the current large observational study of patients with COVID-19, men had more severe status of the COVID-19 than women, and the risk of development of thrombosis was higher in men compared with women, which could be helpful in determining the patient-specific optimal management strategies for COVID-19. - Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
Yuichi Kojima; Sho Nakakubo; Nozomu Takei; Keisuke Kamada; Yu Yamashita; Junichi Nakamura; Munehiro Matsumoto; Hiroshi Horii; Kazuki Sato; Hideki Shima; Masaru Suzuki; Satoshi Konno
Medicina (Kaunas, Lithuania), 58, 4, 2022年04月04日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Background and Objectives: Tocilizumab and baricitinib have been observed to improve the outcomes of patients with coronavirus disease 2019 (COVID-19). However, a comparative evaluation of these drugs has not been performed. Materials and Methods: A retrospective, single-center study was conducted using the data of COVID-19 patients admitted to Hokkaido University hospital between April 2020 and September 2021, who were treated with tocilizumab or baricitinib. The clinical characteristics of the patients who received tocilizumab were compared to those of patients who received baricitinib. Univariate and multivariate logistic regression analyses of the outcomes of all-cause mortality and improvement in respiratory status were performed. The development of secondary infection events was analyzed using the Kaplan-Meier method and the log-rank test. Results: Of the 459 patients hospitalized with COVID-19 during the study, 64 received tocilizumab treatment and 34 baricitinib treatment, and those 98 patients were included in the study. Most patients were treated with concomitant steroids and exhibited the same severity level at the initiation of drug treatment. When compared to each other, neither tocilizumab nor baricitinib use were associated with all-cause mortality or improvement in respiratory status within 28 days from drug administration. Conclusions: Age, chronic renal disease and early administration of TCZ or BRT from the onset of COVID-19 were independent prognostic factors for all-cause mortality, whereas anti-viral drug use and the severity of COVID-19 at baseline were associated with an improvement in respiratory status. Secondary infection-free survival rates of patients treated with tocilizumab and those treated with baricitinib did not significantly differ. The results suggest that both tocilizumab and baricitinib could be clinically equivalent agents of choice in treatment of COVID-19. - COVID-19改善後に発症した遅発性の器質化肺炎を経気管支クライオバイオプシーで診断した3例と文献的考察
堀井 洋志; 中久保 祥; 鎌田 啓佑; 山下 優; 中村 順一; 松本 宗大; 佐藤 一紀; 森永 大亮; 鈴木 雅; 岡崎 ななせ; 高桑 恵美; 松野 吉宏; 今野 哲
日本呼吸器学会誌, 11, 増刊, 169, 169, (一社)日本呼吸器学会, 2022年04月
日本語 - Accuracy of Swan‒Ganz catheterization-based assessment of right ventricular function: Validation study using high-fidelity micromanometry-derived values as reference.
Hideki Shima; Toshitaka Nakaya; Ichizo Tsujino; Junichi Nakamura; Ayako Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Masaru Kato; Isao Yokota; Satoshi Konno
Pulmonary circulation, 12, 2, e12078, 2022年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Right ventricular (RV) function critically affects the outcomes of patients with pulmonary hypertension (PH). Pressure wave analysis using Swan‒Ganz catheterization (SG-cath) allows for the calculation of indices of RV function. However, the accuracy of these indices has not been validated. In the present study, we calculated indices of systolic and diastolic RV functions using SG-cath-derived pressure recordings in patients with suspected or confirmed PH. We analyzed and validated the accuracies of three RV indices having proven prognostic values, that is, end-systolic elastance (Ees)/arterial elastance (Ea), β (stiffness constant), and end-diastolic elastance (Eed), using high-fidelity micromanometry-derived data as reference. We analyzed 73 participants who underwent SG-cath for the diagnosis or evaluation of PH. In this study, Ees/Ea was calculated via the single-beat pressure method using [1.65 × (mean pulmonary arterial pressure) - 7.79] as end-systolic pressure. SG-cath-derived Ees/Ea, β, and Eed were 0.89 ± 0.69 (mean ± standard deviation), 0.027 ± 0.002, and 0.16 ± 0.02 mmHg/ml, respectively. The mean differences (limits of agreement) between SG-cath and micromanometry-derived data were 0.13 (0.99, -0.72), 0.002 (0.020, -0.013), and 0.04 (0.20, -0.12) for Ees/Ea, β, and Eed, respectively. The intraclass correlation coefficients of the indices derived from the two catheterizations were 0.76, 0.71, and 0.57 for Ees/Ea, β, and Eed, respectively. In patients with confirmed or suspected PH, SG-cath-derived RV indices, especially Ees/Ea and β, exhibited a good correlation with micromanometry-derived reference values. - Underdiagnosis of cardiac sarcoidosis by ECG and echocardiography in cases of extracardiac sarcoidosis.
Hiroshi Ohira; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Akiko Hayashishita; Toshitaka Nakaya; Junichi Nakamura; Naoko Suzuki; Ayako Sugimoto; Sho Furuya; Satonori Tsuneta; Taku Watanabe; Ichizo Tsujino; Satoshi Konno
ERJ open research, 8, 2, 2022年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Although screening with 12-lead electrocardiography and transthoracic echocardiography for cardiac involvement has been recommended for patients with biopsy-proven extracardiac sarcoidosis, cardiac sarcoidosis has been reported even in patients with normal electrocardiography and echocardiography findings. We investigated the prevalence and characteristics of these patient cohorts. METHODS: We studied 112 consecutive patients (age, 55±17 years, 64% females) with biopsy-proven extracardiac sarcoidosis who had undergone 18F-fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance imaging for cardiac sarcoidosis evaluation. The patients were categorised as those showing normal findings both in electrocardiography and transthoracic echocardiography (normal group) and those showing abnormal findings in one or both examinations (abnormal group). RESULTS: 33 (29%) and 79 (71%) patients were categorised into the normal and abnormal groups, respectively, of which 6 (18%) and 43 (54%) patients, respectively, were diagnosed with cardiac sarcoidosis (p<0.01). Of these six patients in the normal group, two with multiple-organ sarcoidosis showed clinical deterioration of cardiac involvement and required steroid therapy; three with small cardiac involvement showed natural remission over follow-up assessments; and one underwent steroid therapy and showed an improvement in the left ventricular ejection fraction to within normal limits. CONCLUSIONS: The prevalence of cardiac sarcoidosis in patients with biopsy-proven extracardiac sarcoidosis and normal electrocardiography and transthoracic echocardiography findings was ∼20%. Electrocardiography and transthoracic echocardiography may not detect cardiac sarcoidosis in patients without conduction and morphological abnormalities. However, some of these patients may subsequently show clinically manifested cardiac sarcoidosis. Physicians should be mindful of this population. - 新型コロナウイルス感染症におけるトシリズマブとバリシチニブの治療成績の検討
児島 裕一; 中久保 祥; 鎌田 啓佑; 山下 優; 今野 哲; 武井 望; 中村 順一; 松本 宗大; 堀井 洋志; 佐藤 一紀; 島 秀起; 鈴木 雅
感染症学雑誌, 96, 臨増, 113, 113, (一社)日本感染症学会, 2022年03月
日本語 - 肺動脈圧の上昇が疑われる症例でのEBUS-GS-TBBに伴う出血に関する検討
高島 雄太; 品川 尚文; 山本 岳; 森永 大亮; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 中村 順一; 辻野 一三; 今野 哲
気管支学, 43, 6, 690, 690, (一社)日本呼吸器内視鏡学会, 2021年11月
日本語 - 肺動脈圧の上昇が疑われる症例でのEBUS-GS-TBBに伴う出血に関する検討
高島雄太; 品川尚文; 品川尚文; 山本岳; 森永大亮; 古田恵; 庄司哲明; 朝比奈肇; 菊地英毅; 菊地順子; 榊原純; 中村順一; 辻野一三; 辻野一三; 今野哲
気管支学, 43, 6, 690, 690, (NPO)日本呼吸器内視鏡学会, 2021年11月
日本語 - Right ventricular pressure-volume loop produced with simultaneous application of three-dimensional echocardiography and high-fidelity micromanometry in a patient with pulmonary arterial hypertension.
Toshitaka Nakaya; Ichizo Tsujino; Junichi Nakamura; Yasuyuki Chiba; Hiroyuki Iwano
Echocardiography (Mount Kisco, N.Y.), 38, 5, 805, 807, 2021年05月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Accurate assessment of right ventricular (RV) function has received a growing attention. Pressure-volume (PV) loop analysis is the gold standard method for evaluating RV function; however, it is not widely employed because of its invasive nature and complexity. The present report is the first to have drawn a RV PV loop in a patient with pulmonary hypertension, with a simultaneous recording of RV pressure and volume using high-fidelity micromanometry and three-dimensional echocardiography. This allows for less invasive and simple assessment of RV function, potentially promoting better understanding and management of pulmonary hypertension and other cardiovascular diseases. - Effect of varying storage conditions on diagnostic test outcomes of SARS-CoV-2.
Satoshi Oguri; Shinichi Fujisawa; Keisuke Kamada; Sho Nakakubo; Yu Yamashita; Junichi Nakamura; Hiroshi Horii; Kazuki Sato; Mutsumi Nishida; Takanori Teshima; Yoichi Ohiro; Ayato Takada; Satoshi Konno
The Journal of infection, 83, 1, 119, 145, 2021年04月03日, [査読有り], [国際誌]
英語 - 血気胸を発症したPleuroparenchymal fibroelastosis(PPFE)合併肺癌の1切除例
大塚 慎也; 加藤 達哉; 佐々木 明洋; 山崎 洋; 氏家 秀樹; 藤原 晶; 樋田 泰浩; 加賀 基知三; 若狭 哲; 中村 順一; 篠崎 鮎香; 中久保 祥; 木村 孔一; 渡辺 正明; 岡崎 ななせ; 松野 吉宏
肺癌, 61, 1, 67, 67, (NPO)日本肺癌学会, 2021年02月
日本語 - Successful management of a patient with active Cushing’s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia
Akiko Yuno; Yoshiyuki Kenmotsu; Yuka Takahashi; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; Yu Yamashita; Junichi Nakamura; Sho Nakakubo; Keisuke Kamada; Masaru Suzuki; Hirokazu Sugino; Naoko Inoshita; Satoshi Konno; Hideaki Miyoshi; Tatsuya Atsumi; Yutaka Sawamura; Akira Shimatsu
Endocrine Journal, 68, 4, 477, 484, Japan Endocrine Society, 2021年, [査読有り], [国内誌]
研究論文(学術雑誌) - Proposal of COVID-19 Clinical Risk Score for the management of suspected COVID-19 cases: a case control study.
Sho Nakakubo; Masaru Suzuki; Keisuke Kamada; Yu Yamashita; Junichi Nakamura; Hiroshi Horii; Kazuki Sato; Munehiro Matsumoto; Yuki Abe; Kosuke Tsuji; Nobuhisa Ishiguro; Yasuyuki Nasuhara; Satoshi Konno
BMC infectious diseases, 20, 1, 858, 858, 2020年11月18日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: No clinical scoring system has yet been established to estimate the likelihood of coronavirus disease (COVID-19) and determine the suitability of diagnostic testing in suspected COVID-19 patients. METHODS: This was a single-center, retrospective, observational study of patients with suspected COVID-19 and confirmed COVID-19. Patient background, clinical course, laboratory and computed tomography (CT) findings, and the presence of alternative diagnoses were evaluated. Clinical risk scores were developed based on clinical differences between patients with and without COVID-19. RESULTS: Among 110 patients suspected of having COVID-19, 60.9% underwent polymerase chain reaction (PCR) testing based on the judgment of physicians. Two patients were found to have COVID-19. The clinical characteristics of 108 non-COVID-19 patients were compared with those of 23 confirmed COVID-19 patients. Patients with COVID-19 were more likely to have a history of high-risk exposures and an abnormal sense of taste and smell. The COVID-19 group had significantly higher rates of subnormal white blood cell counts, lower eosinophil counts, and lower procalcitonin levels than the non-COVID-19 group. When blood test results, CT findings, and the presence of alternative diagnoses were scored on an 11-point scale (i.e., "COVID-19 Clinical Risk Score"), the COVID-19 group scored significantly higher than the non-COVID-19 group, more than four points in the COVID-19 group. All non-COVID patients who did not undergo PCR had a score of 4 or less. CONCLUSIONS: The COVID-19 Clinical Risk Score may enable the risk classification of patients suspected of having COVID-19 and can help in decision-making in clinical practice, including appropriateness of diagnostic testing. Further studies and prospective validation with an increased sample size are required. - A histopathological report of a 16-year-old male with peripheral pulmonary artery stenosis and Moyamoya disease with a homozygous RNF213 mutation.
Kei Takahashi; Junichi Nakamura; Shinya Sakiyama; Toshitaka Nakaya; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Keishi Makita; Utano Tomaru; Akihiro Ishizu; Ichizo Tsujino
Respiratory medicine case reports, 29, 100977, 100977, 2020年, [査読有り], [国際誌]
英語, Peripheral pulmonary artery stenosis (PPAS) is a rare pulmonary vasculopathy characterized by multiple stenoses and obstructions in the peripheral pulmonary arteries. PPAS often develops in children with congenital diseases such as Williams syndrome and Alagille syndrome; however, recent studies have reported PPAS cases in adults with Moyamoya disease (MMD). Recent genetic studies have demonstrated that ring finger protein 213 (RNF213) is a susceptibility gene for MMD. However, the pathophysiology of combined PPAS and MMD and the relationship between the two diseases remain largely unknown. Here we report a case of PPAS in a 16-year-old male, with a history of MMD, who died suddenly at 24. An autopsy was performed, and remarkable pathological changes were identified in the pulmonary arteries and in other arteries. Furthermore, genetic analysis revealed that the patient had a homozygous c.14576G > A (p.R4859K) mutation in RNF213. This is the first report to demonstrate the histopathology of systemic arteriopathy in a case with MMD and PPAS with a confirmed homozygous RNF213 mutation. We also review immunohistochemical data from the case and discuss how RNF213 mutation could have resulted in the observed vascular abnormalities. - Pulmonary capillary hemangiomatosis-predominant vasculopathy in a patient with rheumatoid arthritis-associated interstitial lung disease: An autopsy report.
Junichi Nakamura; Ichizo Tsujino; Gaku Yamamoto; Toshitaka Nakaya; Kei Takahashi; Hirokazu Kimura; Takahiro Sato; Taku Watanabe; Shimpei Nakagawa; Noriyuki Otsuka; Hiroshi Ohira; Satoshi Konno
Respiratory medicine case reports, 31, 101215, 101215, 2020年, [査読有り], [国際誌]
英語, Pulmonary capillary hemangiomatosis (PCH) is a rare cause of pulmonary hypertension (PH) associated with poor prognosis. Clinically, it is characterized by severe hypoxemia, centrilobular ground-glass opacities on computed tomography, and pulmonary congestion triggered by pulmonary vasodilating therapy. In some cases, PCH has been reported to develop with other disorders including connective tissue disease; however, to date, no reports have described PCH in a patient with rheumatoid arthritis. We report a case of a 59-year-old male PCH patient with rheumatoid arthritis and associated pulmonary fibrosis. He was initially diagnosed with severe group 3 PH and received sildenafil, which generated a favorable hemodynamic response. However, 5 years later, his pulmonary hemodynamics deteriorated, and he died at the age of 67. An autopsy was performed, and thickening of alveolar septa and capillary proliferation, pathological features of PCH, were extensively observed in both lungs. We discuss when PCH developed, how sildenafil improved his hemodynamics, and how PCH could be clinically detected by noninvasive evaluations. - Rapidly progressive organizing pneumonia associated with COVID-19.
Hiroshi Horii; Keisuke Kamada; Sho Nakakubo; Yu Yamashita; Junichi Nakamura; Yasuyuki Nasuhara; Satoshi Konno
Respiratory medicine case reports, 31, 101295, 101295, 2020年, [査読有り], [国際誌]
英語, We report a case of clinically diagnosed secondary organizing pneumonia (SOP) associated with coronavirus disease 2019 (COVID-19). A 70-year-old woman who had been diagnosed with COVID-19 was admitted to Hokkaido University Hospital. Although her fever, cough, dyspnea, and serum C-reactive protein levels improved, she developed rapidly progressive respiratory failure and computed tomography revealed the development of bilateral lung consolidation. Her dyspnea was relieved, and her oxygenation levels and radiological findings improved after commencing corticosteroid treatment. Blood biomarkers for interstitial lung disease, Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), showed different responses during the clinical course of her disease. Evaluation of serial changes in levels of KL-6 and SP-D may help diagnose and monitor COVID-19-associated organizing pneumonia (OP). Clinicians should be aware that SOP can develop in response to COVID-19 and that these patients may benefit from the use of steroids.
- 心室中隔欠損症閉鎖術後遠隔期に肺動脈拡張と重症肺動脈弁閉鎖不全症を発症した一例
下野 裕依; 石坂 傑; 松浦 勇匡; 宮本 郁未; 田原 就; 神林 諒; 玉置 陽生; 常田 慧徳; 中村 順一; 加藤 伸康; 永井 利幸; 辻野 一三; 若狭 哲; 安斉 俊久, 日本成人先天性心疾患学会雑誌, 15, 1, 149, 149, 2026年01月
(一社)日本成人先天性心疾患学会, 日本語 - 肺腫瘍血栓性微小血管症が疑われたEGFR遺伝子変異陽性非小細胞肺癌の1例
福井 伸明; 庄司 哲明; 中村 友彦; 中村 順一; 中久保 祥; 池澤 靖元; 榊原 純; 辻野 一三; 今野 哲; 種井 善一; 田中 伸哉, 肺癌, 65, 7, 1096, 1096, 2025年12月
(NPO)日本肺癌学会, 日本語 - 当科のサルコイドーシス組織診断症例における悪性腫瘍発症に関する研究
中村 友彦; 佐藤 隆博; 稲尾 翼; 小森 卓; 吉川 修平; 中村 順一; 辻野 一三; 横田 勲; 今野 哲, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 45, サプリメント号, 69, 69, 2025年10月
日本サルコイドーシス, 日本語 - 肺サルコイドーシス組織診断例における性別・心臓病変合併の生命予後への影響
吉川 修平; 佐藤 隆博; 辻野 一三; 中村 順一; 小森 卓; 木村 孔一; 今野 哲, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 45, サプリメント号, 69, 69, 2025年10月
日本サルコイドーシス, 日本語 - COPDに対し気管支バルブによる気管支鏡的肺容量減量術を試みた2症例
吉川 修平; 中村 友彦; 高島 雄太; 小森 卓; 三田 明音; 若園 順康; 松本 宗大; 中村 順一; 中久保 祥; 木村 孔一; 品川 尚文; 辻野 一三; 今野 哲, 気管支学, 47, 3, 259, 259, 2025年05月
(一社)日本呼吸器内視鏡学会, 日本語 - ペースメーカー感染により肺塞栓を繰り返したCTEPHの1例
佐藤隆博; 佐藤隆博; 小森卓; 島秀起; 中村順一; 直亨則; 中久保祥; 若林健人; 辻野一三; 辻野一三; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - 第4群肺高血圧症のBPA前後における合成心電図V3R,V4R,V5Rの検討
原田亜実; 佐藤隆博; 佐藤隆博; 三谷麻子; 岩井孝仁; 井上真美子; 中村順一; 今野哲; 今野哲; 辻野一三; 辻野一三; 山下直樹; 豊嶋崇徳, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - 肺病変合併肺動脈性肺高血圧症の臨床的特徴および予後
小森卓; 辻野一三; 吉川修平; 島秀起; 中村順一; 杉本絢子; 佐藤隆博; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - CTEPHに対するBPA後の6分間歩行距離の変化と身体所見の関係
藤内宏典; 堀弘明; 小森卓; 島秀起; 中村順一; 杉本絢子; 佐藤隆博; 佐藤隆博; 辻野一三; 辻野一三; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - 慢性血栓塞栓性肺高血圧症患者における肺血管拡張薬の短期効果
島秀起; 佐藤隆博; 佐藤隆博; 小森卓; 吉川修平; 中村順一; 辻野一三; 辻野一三; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - 肺高血圧症(平均肺動脈圧>20mmHg)の心電図所見の検討
三谷麻子; 佐藤隆博; 佐藤隆博; 原田亜実; 岩井孝仁; 井上真美子; 中村順一; 今野哲; 今野哲; 辻野一三; 辻野一三; 山下直樹; 豊嶋崇徳, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - エポプロステノールを離脱したSLEによる肺高血圧症の一例
吉川修平; 佐藤隆博; 小森卓; 島秀起; 中村順一; 辻野一三; 馬詰武; 安田充孝; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - 左右で病型が異なったCTEPHの2症例
中村順一; 小森卓; 吉川修平; 島秀起; 佐藤隆博; 佐藤隆博; 大岡智学; 辻野一三; 辻野一三; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年 - 深層学習を用いた心尖部四腔像からの右室駆出率の推定
村山迪史; 村山迪史; 加賀早苗; 加賀早苗; 向井葵; 永井優衣; 杉森博行; 吉村高明; 島秀起; 常田慧徳; 西野久雄; 中村順一; 佐藤隆博; 辻野一三, 日本超音波検査学会学術集会講演抄録集(Web), 49th, 2024年 - 慢性血栓塞栓性肺高血圧症の臨床経過や予後に対して癌が及ぼす影響の検討
中村順一; 辻野一三; 辻野一三; 島秀起; 中谷資隆; 杉本絢子; 佐藤隆博; 佐藤隆博; 渡部拓; 大平洋; 鈴木雅; 横田勲; 今野哲; 今野哲, 日本呼吸器学会誌(Web), 13, 2024年 - 肺サルコイドーシス組織診断例における心病変合併例の割合および臨床的特徴
吉川修平; 佐藤隆博; 辻野一三; 中村順一; 永井利幸; 木村孔一; 今野哲, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 44, 2024年 - 気管支動脈瘤を伴った肺高血圧症の2例
玉槻大輔; 佐藤隆博; 辻野一三; 島秀起; 中村順一; 阿保大介; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 9th (CD-ROM), 2024年 - PAHにおける間質性肺疾患合併の割合および臨床的意義
小森卓; 島秀起; 中村順一; 杉本絢子; 佐藤隆博; 辻野一三; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 9th (CD-ROM), 2024年 - CTEPHの予後に対する癌の影響-CTEPH AC registryにおける検討-
中村順一; 辻野一三; 眞崎耕平; 谷口悠; 足立史郎; 伊波巧; 細川和也; 山下淳; 矢尾板信裕; 阿部弘太郎, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 9th (CD-ROM), 2024年 - 肺血管拡張療法がPAHと3群PHの右室機能および予後に与える影響
島秀起; 辻野一三; 辻野一三; 中村順一; 佐藤隆博; 佐藤隆博; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 9th (CD-ROM), 2024年 - 呼吸と循環のCross road:肺高血圧症の臨床と基礎の最前線 間質性肺疾患に伴う肺高血圧症の剖検例における肺血管病変の病理学的解析
杉本 絢子; 辻野 一三; 中村 順一; 佐藤 隆博; 鈴木 雅; 高村 圭; 岩崎 沙理; 種井 善一; 谷口 浩二; 田中 伸哉; 今野 哲, 日本呼吸器学会誌, 12, 増刊, 44, 44, 2023年03月
(一社)日本呼吸器学会, 日本語 - 肺動脈性肺高血圧症における肺拡散能力低下の機序及び臨床的意義
杉本絢子; 辻野一三; 辻野一三; 島秀起; 中村順一; 佐藤隆博; 佐藤隆博; 清水薫子; 横田卓; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 8th, 2023年 - PVOD/PCHに対してイマチニブを使用した5症例の検討
中村順一; 辻野一三; 辻野一三; 島秀起; 杉本絢子; 佐藤隆博; 佐藤隆博; 大平洋; 鈴木雅; 常田慧徳; 久田諒; 加藤将; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 8th, 2023年 - 肺疾患合併肺高血圧症における右室機能と予後に関する検討
島秀起; 辻野一三; 辻野一三; 中村順一; 佐藤隆博; 佐藤隆博; 鈴木雅; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 8th, 2023年 - 間質性肺疾患合併肺高血圧症に特徴的な肺血管病変とその発生機序に関する検討
杉本絢子; 辻野一三; 辻野一三; 中村順一; 佐藤隆博; 佐藤隆博; 鈴木雅; 高村圭; 谷口浩二; 田中伸哉; 今野哲, 日本呼吸器学会誌(Web), 12, 2023年 - 間質性肺疾患に伴う肺高血圧症の剖検例における肺血管病変の病理学的解析
杉本絢子; 辻野一三; 辻野一三; 中村順一; 佐藤隆博; 佐藤隆博; 鈴木雅; 高村圭; 岩崎沙理; 種井善一; 谷口浩二; 田中伸哉; 今野哲; 今野哲, 日本呼吸器学会誌(Web), 12, 2023年 - 脈管疾患における抗凝固療法の進歩 COVID-19と抗凝固療法 日本での新型コロナウイルス感染症と静脈血栓塞栓症 タスクフォース実態調査報告を含めて
孟 真; 山下 侑吾; 小林 隆夫; 小川 智弘; 山田 典一; 中田 弘子; 佐戸川 弘之; 池田 聡司; 山本 尚人; 谷地 繊; 竹山 誠; 西本 裕二; 林 浩也; 中村 順一; 辻野 一三; 梅津 道久; 荻原 義人; 池田 長生; 相川 志都; 岩田 英理子, 脈管学, 62, Suppl., S106, S106, 2022年10月
(一社)日本脈管学会, 日本語 - COVID-19と血栓症 総論、海外と我が国のデータ
谷地 繊; 竹山 誠; 山下 侑吾; 西本 裕二; 辻野 一三; 中村 順一; 山本 尚人; 中田 弘子; 池田 聡司; 梅津 道久; 相川 志都; 林 浩也; 佐戸川 弘; 奥野 善教; 岩田 英理子; 荻原 義人; 池田 長生; 近藤 朱音; 岩井 武尚; 山田 典一; 小川 智弘; 小林 隆夫; 孟 真, 静脈学, 33, 2, 144, 144, 2022年06月
(一社)日本静脈学会, 日本語 - COVID-19患者における入院時D-ダイマーの重要性
池田 長生; 谷地 繊; 竹山 誠; 西本 裕二; 辻野 一三; 中村 順一; 山本 尚人; 中田 弘子; 池田 聡司; 梅津 道久; 相川 志都; 林 浩也; 佐戸川 弘; 奥野 善教; 岩田 英理子; 荻原 義人; 近藤 朱音; 岩井 武尚; 山田 典一; 小川 智弘; 小林 隆夫; 孟 真; 山下 侑吾, 静脈学, 33, 2, 148, 148, 2022年06月
(一社)日本静脈学会, 日本語 - COVID-19改善後に発症した遅発性の器質化肺炎を経気管支クライオバイオプシーで診断した3例と文献的考察
堀井洋志; 中久保祥; 鎌田啓佑; 山下優; 中村順一; 松本宗大; 佐藤一紀; 森永大亮; 鈴木雅; 岡崎ななせ; 高桑恵美; 松野吉宏; 今野哲, 日本呼吸器学会誌(Web), 11, 2022年 - 間質性肺疾患への肺高血圧症合併における肺小血管リモデリングの寄与
杉本絢子; 辻野一三; 大塚紀幸; 石田雄介; 中村順一; 中谷資隆; 佐藤隆博; 大平洋; 鈴木雅; 高村圭; 田中伸哉; 今野哲, 日本呼吸器学会誌(Web), 11, 2022年 - CLOT-COVID studyにおける大出血例の検討
中村順一; 辻野一三; 児島裕一; 島秀起; 中久保祥; 今野哲, 静脈学(Web), 33, 2, 2022年 - 静脈および動脈血栓症の分析:CLOT-COVID Studyより
梅津道久; 山下侑吾; 谷地繊; 竹山誠; 西本裕二; 辻野一三; 中村順一; 山本尚人; 中田弘子; 池田聡司; 相川志都; 林浩也; 佐戸川弘之; 奥野善教; 岩田英理子; 荻原義人; 池田長生; 近藤朱音; 岩井武尚; 山田典一; 小川智弘; 小林隆夫; 孟真, 静脈学(Web), 33, 2, 2022年 - COVID-19と血栓症:総論,海外と我が国のデータ
谷地繊; 竹山誠; 山下侑吾; 西本裕二; 辻野一三; 中村順一; 山本尚人; 中田弘子; 池田聡司; 梅津道久; 相川志都; 林浩也; 佐戸川弘; 奥野善教; 岩田英理子; 荻原義人; 池田長生; 近藤朱音; 岩井武尚; 山田典一; 小川智弘; 小林隆夫; 孟真, 静脈学(Web), 33, 2, 2022年 - COVID-19患者における入院時D-ダイマーの重要性
池田長生; 谷地繊; 竹山誠; 西本裕二; 辻野一三; 中村順一; 山本尚人; 中田弘子; 池田聡司; 梅津道久; 相川志都; 林浩也; 佐戸川弘; 奥野善教; 岩田英理子; 荻原義人; 近藤朱音; 岩井武尚; 山田典一; 小川智弘; 小林隆夫; 孟真; 山下侑吾, 静脈学(Web), 33, 2, 2022年 - 呼吸器難病の課題と展望 肺動脈性肺高血圧症の現状と課題
中村順一; 辻野一三; 辻野一三, 月刊呼吸器内科, 42, 5, 2022年 - COVID-19と抗凝固療法 日本での新型コロナウイルス感染症と静脈血栓塞栓症-タスクフォース実態調査報告を含めて-
孟真; 孟真; 山下侑吾; 小林隆夫; 小川智弘; 山田典一; 中田弘子; 中田弘子; 佐戸川弘之; 池田聡司; 山本尚人; 谷地繊; 竹山誠; 西本裕二; 林浩也; 中村順一; 辻野一三; 梅津道久; 荻原義人; 池田長生; 相川志都; 岩田英理子, 脈管学(Web), 62, supplement, 2022年 - 右室収縮/拡張能の評価に最も適切な心エコー指標は何か?
島秀起; 辻野一三; 中谷資隆; 三浦瞬; 堀井洋志; 中村順一; 佐藤隆博; 大平洋; 千葉泰之; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 7th, 2022年 - 肺高血圧合併間質性肺疾患における肺血管病変の病理学的解析
杉本絢子; 辻野一三; 辻野一三; 大塚紀幸; 中村順一; 佐藤隆博; 大平洋; 鈴木雅; 高村圭; 石田雄介; 田中伸哉; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 7th, 2022年 - Nottingham型不安定ヘモグロビン症に合併した肺高血圧症の一例
三浦瞬; 佐藤隆博; 島秀起; 中村順一; 中谷資隆; 渡部拓; 大平洋; 橋本大吾; 辻野一三; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 7th, 2022年 - 北海道大学病院におけるPVOD/PCH11症例の検討
中村順一; 辻野一三; 島秀起; 中谷資隆; 杉本絢子; 佐藤隆博; 渡部拓; 鈴木雅; 大平洋; 常田慧徳; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 7th, 2022年 - 両側滲出性胸水と全身浮腫で発症し、局所麻酔下胸腔鏡でサルコイドーシスと診断した一例
篠崎 鮎香; 木村 孔一; 山下 優; 堀井 洋志; 佐藤 一紀; 中村 順一; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 中里 信一; 松野 吉宏; 山口 哲夫; 大橋 健一; 江石 義信; 今野 哲, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 41, サプリメント号, 67, 67, 2021年10月
日本サルコイドーシス, 日本語 - 血気胸を発症したPleuroparenchymal fibroelastosis(PPFE)合併肺癌の1切除例
大塚 慎也; 加藤 達哉; 佐々木 明洋; 山崎 洋; 氏家 秀樹; 藤原 晶; 樋田 泰浩; 加賀 基知三; 若狭 哲; 中村 順一; 篠崎 鮎香; 中久保 祥; 木村 孔一; 渡辺 正明; 岡崎 ななせ; 松野 吉宏, 肺癌, 61, 1, 67, 67, 2021年02月
(NPO)日本肺癌学会, 日本語 - 肝移植後にPleuroparenchymal fibroelastosis(PPFE)合併肺癌を発症した一例
大塚慎也; 加藤達哉; 氏家秀樹; 椎谷洋彦; 加賀基知三; 若狭哲; 中村順一; 中久保祥; 木村孔一; 渡辺正明; 嶋村剛; 岡崎ななせ; 松野吉宏; 田中敏, 日本移植学会総会(Web), 57th, 2021年 - 間質性肺疾患合併肺高血圧症の肺血管形態に関する病理学的検討
杉本絢子; 辻野一三; 大塚紀幸; 中村順一; 中谷資隆; 佐藤隆博; 渡部拓; 大平洋; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 6th, 2021年 - 北海道大学病院における肺高血圧症の臨床分類と生存率の報告
大平洋; 中村順一; 杉本絢子; 中谷資隆; 鈴木雅; 加藤将; 辻野一三; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 6th, 2021年 - 肺高血圧症の死因解析-各群の特徴を実臨床でどう活かすか
中村順一; 辻野一三; 中谷資隆; 杉本絢子; 佐藤隆博; 鈴木雅; 渡部拓; 大平洋; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 6th, 2021年 - 末梢型肺動脈狭窄症を合併したもやもや病の一剖検例
石津明洋; 外丸詩野; 田中敏; 牧田啓史; 高橋桂; 崎山信哉; 中村順一; 中谷資隆; 林下晶子; 渡部拓; 大平洋; 辻野一三, 脈管学(Web), 60, 2, 2020年 - 2型糖尿病患者におけるイプラグリフロジンと高用量メトホルミンの有効性の比較検討
中谷資隆; 渡部拓; 渡部拓; 長谷川敦; 吉村治彦; 池田大輔; 坂上慎二; 一宮由紀子; 本多敏朗; 藤原豊; 高階知紗; 合田晶; 佐藤文彦; 藤本晶子; 広川淳一; 鈴木奈緒子; 中村順一; 杉本絢子; 林下晶子; 大平洋; 辻野一三; 辻野一三; 西村正治; 今野哲, 糖尿病(Web), 63, Suppl, 2020年 - もやもや病に合併した末梢型肺動脈狭窄症の1例
中村順一; 崎山信哉; 中谷資隆; 高橋桂; 林下晶子; 渡部拓; 大平洋; 牧田啓史; 外丸詩野; 石津明洋; 辻野一三, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 39, 1-2, 2019年 - Fusobacterium nucleatumによる膿胸を発症した2型糖尿病の1例
崎山信哉; 渡部拓; 長岡健太郎; 中村順一; 中谷資隆; 林下晶子; 鈴木雅; 大平洋; 今野哲; 辻野一三, 糖尿病(Web), 62, 12, 2019年 - 高齢2型糖尿病患者における骨格筋量・体脂肪率と基礎代謝量,インスリン抵抗性との関連の評価
林下晶子; 渡部拓; 崎山信哉; 中村順一; 中谷資隆; 鈴木奈緒子; 杉本絢子; 大平洋; 辻野一三, 糖尿病(Web), 62, Suppl, 2019年 - 心電図,心エコーによる心サルコイドーシスのスクリーニングは十分か?
大平洋; 崎山信哉; 中谷資隆; 鈴木奈緒子; 中村順一; 杉本絢子; 林下晶子; 渡部拓; 今野哲; 辻野一三, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 38, 2018年 - 重症3群肺高血圧症の右室形態と収縮能への肺血管拡張療法の効果
杉本絢子; 辻野一三; 中村順一; 佐藤隆博; 大平洋; 渡部拓; 鈴木雅; 今野哲; 西村正治, 呼吸と循環, 64, 5, 2016年 - 自然退縮を認めた,癌関連網膜症合併小細胞肺癌の1例
中村順一; 北井秀典; 榊原純; 水柿秀紀; 大泉聡史; 西村正治; 廣橋良彦; 佐藤昇志; 齋藤航; 神田敦宏, 肺癌(Web), 54, 7, 990(J‐STAGE), 990, 2014年12月
(NPO)日本肺癌学会, 日本語 - 自然退縮を示した,癌関連網膜症合併小細胞肺癌の1例
中村順一; 北井秀典; 榊原純; 水柿秀紀; 大泉聡史; 廣橋良彦; 齋藤航; 神田敦宏; 佐藤昇志; 西村正治, 日本肺癌学会総会号, 55th, 5, 508, 508, 2014年10月05日
(NPO)日本肺癌学会, 日本語
